The Development of Metal Complexes as Components of Fluorescent and Nuclear Imaging Probes by Turnbull, William
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
8-14-2018 10:00 AM 
The Development of Metal Complexes as Components of 
Fluorescent and Nuclear Imaging Probes 
William Turnbull 
The University of Western Ontario 
Supervisor 
Luyt, Leonard G. 
The University of Western Ontario 
Graduate Program in Chemistry 
A thesis submitted in partial fulfillment of the requirements for the degree in Doctor of 
Philosophy 
© William Turnbull 2018 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Organic Chemistry Commons 
Recommended Citation 
Turnbull, William, "The Development of Metal Complexes as Components of Fluorescent and Nuclear 
Imaging Probes" (2018). Electronic Thesis and Dissertation Repository. 5517. 
https://ir.lib.uwo.ca/etd/5517 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
i 
 
Abstract 
The advent of molecular imaging as a discipline has drastically improved our ability to 
understand the biochemical and cellular events that drive life, death and disease. This thesis 
will document the discovery of new metal chelators for Re/99mTc, new methods of 
incorporating these metals into peptide structures, as well as new fluorescent compounds. 
These novel methods and compounds may be used in the development of molecular imaging 
probes for single photon emission computed tomography (SPECT) and optical imaging 
techniques, with applications for differentiating cancerous tissue from benign and healthy. 
Chapter 2 discusses the development of a dual modality Re/99mTc imaging probe for 
fluorescence/SPECT imaging for evaluating CXCR4 expression in cancer cells. The T140 
derivative contains a 4-amino-1,8-naphthalimide chelator to bind rhenium or technetium-99m 
for fluorescence or SPECT imaging. The rhenium coordinated peptide retained high affinity 
for CXCR4 and was able to detect cells expressing the receptor by fluorescence microscopy. 
However, little uptake of the technetium-99m labelled peptide was observed in CXCR4 
expressing tumors in a murine model. 
Chapter 3 aims to address the shortcomings of the naphthalimide chelation system discussed 
in chapter 2. Three 4-amino-1,8-naphthalimides containing chelators with a positive, neutral 
or negative charge were synthesized and coordinated with rhenium. All three complexes had 
photophysical properties that were compatible with confocal fluorescence microscopy and 
showed uptake in cells that was dependent on charge. All three ligands were radiolabelled with 
technetium-99m in high radiochemical yield and purity. 
Chapter 4 discusses the development of a b-hairpin forming peptide containing a 2,2’-
bipyridine moiety to chelate Re/99mTc. A novel amino acid based on 3,3’-diamino-2,2’-
bipyridine was synthesized, and incorporated into a peptide. Circular dichroism spectroscopy 
indicated a lack of secondary structure, but formation of secondary structures resembling a b-
sheet was possible upon the addition of 2,2,2-trifluoroethanol (TFE). However, metal 
coordination resulted in unstable complexes that were unable to be isolated. 
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Chapter 5 discusses the development of 2,2’-bipyridine-based fluorophores for the detection 
of intracellular Zn(II). Two benzimidazole functionalized bipyridines were found to have a 
fluorescence response to Zn(II) that was compatible for detection by confocal fluorescence 
microscopy. Both ligands displayed fluorescence in benign prostate cells due to Zn(II) 
coordination but not in prostate cancer cells. These ligands are promising candidates for the 
detection of Zn(II) in ex vivo prostate tissues for differentiating malignant tissue from benign 
and healthy. 
Keywords 
Molecular Imaging Probes, CXCR4, Rhenium, Technetium-99m, Zinc, Fluorescence, SPECT, 
Bipyridine, Naphthalimide, Peptide 
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Chapter 1  
1 Introduction 
1.1 Molecular Imaging 
Living organisms are a complex medley of synergistic biochemical and cellular events, and 
unveiling these processes that drive life, death and disease is a formidable task. In the past, 
our progress towards this goal had been impaired by our inability to observe these 
processes in living organisms as they occur, without perturbing the natural environment in 
which they take place. The advent of molecular imaging as a discipline has drastically 
improved our ability to understand these processes. While the precise definition of the term 
molecular imaging may be different amongst various researchers and scientists, the 
definition put forth by Gambhir & James will be used here: the non-invasive, real-time 
visualization of biochemical processes at the cellular and molecular level within living 
cells, tissues or organisms.1 Not only do molecular imaging techniques allow for 
fundamental research into biochemical and cellular processes, they also have use in a 
clinical setting, allowing for the diagnosis and monitoring of disease which can be used to 
devise treatments that may preclude the need for invasive procedures such as biopsies.  
Molecular imaging is an incredibly broad field that encompasses a number of imaging 
modalities including, but not limited to: positron emission tomography (PET), single 
photon emission computed tomography (SPECT), magnetic resonance imaging (MRI) and 
optical fluorescence imaging (OI). Each of these imaging modalities has its own inherent 
strengths and weaknesses in terms of molecular sensitivity and spatial resolution (Figure 
1.1) as well as depth of tissue penetration and cost.2 Nuclear imaging modalities such as 
PET and SPECT offer remarkable sensitivity and unlimited tissue penetration at the cost 
of requiring ionizing radiation. MRI techniques do not require ionizing radiation but suffer 
from low sensitivity. OI has limited clinical use due to the limited depth of tissue 
penetration. 
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Figure 1.1: Comparison of spatial resolution and molecular sensitivity between imaging 
modalities.  
1.2 Molecular Imaging Probes 
Molecular imaging modalities often require a method to create a signal or image contrast 
that is detectable by external detectors. In order for this signaling entity to reach the organs, 
tissues or cellular compartments of interest it must be chemically attached to a targeting 
entity that is able to interact with molecular targets in the region of interest. These 
molecular targets may be receptors, transporters or enzymes. The combination of a 
targeting entity and signaling entity for the purpose of molecular imaging is called a 
molecular imaging probe, though other terms such as molecular imaging agent are often 
used. Figure 1.2 depicts three examples of molecular imaging probes. Further details about 
the targeting and signaling entities will be presented in this section. 
1.2.1 Targeting Entity 
The choice of targeting entity is critical, as this component can determine many of the 
pharmacological properties of the molecular imaging agent. While it is difficult to predict 
the pharmacokinetics of an imaging agent, it is widely acknowledged that molecular size, 
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charge, lipophilicity and binding affinity to the target of interest are all contributing 
factors.3–6 The most common targeting entities are derived from small molecules, peptides 
or monoclonal antibodies (mAbs).  
 
Figure 1.2: Examples of molecular imaging probes for PET ([18F]FDG), SPECT 
([99mTc]Tc-HYNIC-TOC) and OI (RGD-Cy5.5). 
Small molecules (usually <500 Da) typically offer good pharmacokinetic properties such 
as fast accumulation in the target tissues, and quick clearance from the vasculature, giving 
good signal-to-background contrast.1 However, due to their small size, they are often 
limited in the type of signaling components that may be incorporated, as large fluorophores 
and metal chelators can negatively impact the small molecule’s ability to bind to and reach 
its target. On the opposite end of the spectrum, mAbs are typically on the size range of 150 
kDa, and due to their large size, may be appended with large fluorophores and metal 
chelators without affecting the incredibly high affinity and specificity that they have for 
their molecular targets. However, mAbs have long biological half-lives (typically days to 
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weeks) and are retained in the blood for long periods of time which can result in low signal-
to-background ratios, and therefore poor quality images.7 Peptides have found a place as 
the “best of both worlds” between small molecules and mAbs. They offer the benefits of 
small molecules such as membrane permeability and fast clearance kinetics, but retain the 
high stability, target specificity and tolerance towards modification that mAbs possess.8,9 
Peptides are also easily synthesized by solid-phase peptide synthesis, and are easily 
modified to improve in vivo stability, pharmacokinetics and affinity for the molecular target 
of interest. 
1.2.2 Signaling Entity 
A wide variety of signaling entities are available depending on the chosen imaging 
modality. Optical imaging requires the addition of a fluorescent molecule to the targeting 
entity. For in vitro cellular microscopy, fluorophores with emission wavelengths ranging 
from 400-600 nm are most widely used such as fluorescein isothiocyanate (FITC), 7-
amino-4-methylcoumarin (AMC) and 5-carboxytetramethylrhodamine (TAMRA) (Figure 
1.3, A-C). For in vivo imaging applications however, wavelengths in the near infrared 
(NIR) window (650-900 nm) are required due to signal attenuation by tissues in the visible 
range.10 Far-red cyanine dyes are the most commonly used fluorophores for this purpose.11 
Various chemical methods such as amidation, thiourea formation, and click chemistry may 
be used to conjugate fluorophores to targeting entities such as peptides and mAbs.12,13  
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Figure 1.3: Structures of some common fluorophores (A-C), bifunctional chelators (D-F) 
and prosthetic groups (G and H) used in signaling components of molecular imaging 
probes. (A) Fluorescein isothiocyanate (FITC), (B) 7-amino-4-methylcoumarin (AMC), 
(C) 5-carboxytetramethylrhodamine (TAMRA), (D) 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA), (E) diethylenetriaminepentaacetic acid (DTPA), (F) 
[bis(pyridine-2-ylmethyl)amino]acetic acid (BPA), (G) N-succinimidyl [18F]4-
fluorobenzoate ([18F]SFB), (H) [11C]methyl iodide. 
Four common strategies are employed for incorporating radioisotopes into targeting 
molecules: pendant labelling, prosthetic group labelling, direct labelling and integrated 
labelling (Figure 1.4).9 Pendant labelling is commonly employed with radiometals for 
labelling of peptides and mAbs. This method involves the attachment of a bifunctional 
chelator to the targeting entity in a location away from the biologically active site. 
Examples of bifunctional chelators include 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA), diethylenetriaminepentaacetic acid (DTPA), and [bis(pyridine-2-
ylmethyl)amino]acetic acid (BPA) (Figure 1.3, D-F). For a peptide, these chelators are 
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typically connected to one of the termini, or an amino acid side-chain such as a lysine side-
chain. Some examples of molecules labelled by this method include somatostatin 
derivatives such as [99mTc]Tc-HYNIC-TOC14 and the CXCR4 targeting peptide [68Ga]Ga-
Pentixafor.15 This method can be problematic as it results in an increase in the molecular 
weight and size of the molecule, and can affect binding to the target of interest. An 
integrated labelling approach may be used to mitigate the effects of pendant labelling. This 
method attempts to “hide” a radioisotope within the framework of the targeting entity, often 
using a radiometal to induce the formation of secondary structure in a protein or peptide, 
or stabilize already present secondary structures.16–18 An integrated approach has also been 
employed in steroid mimics targeting the estrogen receptor.19–21 This approach of 
concealing the radioisotope would ideally have little effect on the affinity of the targeting 
entity to the molecular target. Radionuclides such as 18F and 11C are most commonly 
incorporated into imaging agents through the prosthetic group labelling approach. This 
involves the radiolabelling of a small molecule “prosthetic group” containing a reactive 
group which may then be conjugated to the targeting entities. N-succinimidyl [18F]4-
fluorobenzoate ([18F]SFB)22 and [11C]methyl iodide23 (Figure 1.3, G and H) are common 
prosthetic groups employed for radiolabelling of peptides, proteins and small molecules. 
Direct labelling approaches are typically involved in the radiosynthesis of small molecules 
such as [18F]2-fluoro-2-deoxyglucose ([18F]FDG),24 where a leaving group is directly 
displaced with the radionuclide. There are however, several published methods for the 
direct labelling of peptides and other biomolecules.25–27  
A wide range of methodologies are available for combining a signaling entity with a 
targeting entity for the creation of molecular imaging probes. The choice of method 
strongly depends on the molecular target of interest, the desired pharmacokinetic 
properties, and the available ligands that can bind to the molecular target. 
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Figure 1.4: Methods for incorporating a radioisotope into PET and SPECT molecular 
imaging probes. Pendant and integrated methods are often employed when using 
radiometals such as 68Ga and 99mTc, while prosthetic group and direct labelling are 
employed with non-metal radioisotopes such as 11C and 18F. 
1.3 Single Photon Emission Computed Tomography 
Single photon emission computed tomography (SPECT) imaging is the most widely used 
imaging modality in nuclear medicine due to the availability of on-site generators to 
produce the required radionuclides. Gamma-emitting radionuclides such as 99mTc (t1/2 = 6 
hrs), 111In (t1/2 = 2.8 days) and 123I (t1/2 = 13.2 hrs) are employed for this modality. Their 
decay energies, which range from 100 to 300 keV, are optimal for tissue penetration, while 
being relatively innocuous to the subject.28  These isotopes are typically produced in an on-
site generator or by a cyclotron. SPECT radioisotopes tend to be longer lived than PET 
radioisotopes, with half-lives ranging from 6 hours to 3 days.9 This is sufficient time for 
radiosynthesis, purification and administration to patients, followed by biodistribution and 
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imaging. The longer half-lives of SPECT isotopes also provide the opportunity for imaging 
over longer periods of time.  
Gamma-emitting isotopes produce gamma-rays unidirectionally, requiring the detector (a 
gamma camera) to be rotated around the subject, collecting images from multiple angles 
for 3D reconstruction. Signal attenuation is a common problem in SPECT, as collimators 
are required to exclude gamma rays that have been scattered. This results in lower 
sensitivity than PET, and makes quantitative information nearly impossible to gather.29,30 
Despite these shortcomings, SPECT imaging is an integral technique in nuclear medicine 
due to its wide availability, and relatively low cost. 
1.4 Technetium-99m 
Technetium-99m is considered a workhorse radionuclide in nuclear medicine. In the late 
1990s to early 2000s, it accounted for approximately 80% of radiopharmaceuticals used 
clinically and 85% of diagnostic nuclear imaging procedures in hospitals.31,32 Technetium-
99m emits gamma rays with a decay energy of 140 keV, which is considered optimal for 
imaging with gamma cameras, and has a half-life of 6 hours. This half-life is long enough 
for preparation and administration of the imaging agent, while minimizing the absorbed 
radiation dose. Technetium-99m is typically produced by radioactive decay of 
molybdenum-99 in a generator system.33,34 In recent years, cyclotron production of 
technetium-99m has been explored as an alternative.35 From the more common generator 
system, molybdenum-99 decays by b- decay (t1/2 = 66 h) to technetium-99m. This 
metastable nuclear isomer decays to the ground state technetium-99 predominantly by 
emission of a 140 keV gamma ray. Technetium-99 subsequently decays with an 
exceptionally long half-life of 2.12 x 105 years to the stable ruthenium-99 by b- decay 
(Figure 1.5). 
The technetium-99m is eluted from a 99Mo/99mTc generator in the form of sodium 
pertechnetate ([99mTc]NaTcO4), where the technetium is in the synthetically inaccessible 
+7 oxidation state and must be reduced to a lower oxidation state for incorporation into 
radiopharmaceuticals. Oxidation states ranging from -1 to +7 are accessible for technetium, 
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though for medical applications the +1, +3 and +5 oxidation states are used most 
commonly.36 
 
Figure 1.5: Radioactive decay scheme of 99Mo to the stable isotope 99Ru. 
Technetium-99m radiopharmaceuticals can be classified into two categories: “99mTc-
essential” and “99mTc-tagged” radiopharmaceuticals. In the former, the technetium-99m is 
an integral component of the radiopharmaceutical. Neither the technetium-99m nor the 
ligand on its own can reach the target of interest, only after metal coordination to the ligand 
does the agent have the desired pharmacological properties. Perfusion agents such as 
[99mTc]Tc-MAG337 and [99mTc]-Sestamibi38 are classical examples of “99mTc-essential” 
radiopharmaceuticals (Figure 1.6, Top). 99mTc-labelled molecular imaging probes labelled 
through the integrated method may be considered as “99mTc-essential” as well. 
“99mTc-tagged” radiopharmaceuticals are in the same vein as pendant labelled molecular 
imaging probes, where a bifunctional chelator is conjugated to a targeting entity that guides 
the radioisotope to the molecular target of interest. [99mTc]Tc-HYNIC-TOC,14 
[99mTc]TROD-AT-139 and [99mTc]Tc(CO)3(MIP-1404)40 (Figure 1.6, Bottom) are some 
notable examples of “99mTc-tagged” radiopharmaceuticals. “99mTc-tagged” 
radiopharmaceuticals commonly contain metal complexes with 99mTc in the +3 or +5 
10 
 
oxidation states due to their ease of labelling and purification, as well as the availability of 
kit formulations. 
 
Figure 1.6: Examples of “99mTc-essential” and “99mTc-tagged” radiopharmaceuticals. 
Many of these complexes however, suffer from low stability in solution and in vivo41,42 or 
contain multiple isomeric forms that may differ in their biological activity.43 In the late 
1990’s Schubiger et al developed the fac-technetium(I) tricarbonyl core as an alternative.44 
fac-[Tc(H2O)3(CO)3]+ was produced in a single step from NaTcO4 by reduction with 
NaBH4 in aqueous solution under CO atmosphere. Other reagent systems have been 
developed that do not require reaction under CO atmosphere and are therefore more 
suitable for the synthesis of radiopharmaceuticals in a clinical setting.45 fac-
[Tc(H2O)3(CO)3]+ was demonstrated to be stable in aqueous solution at a pH range from 1 
to 13 for several hours, and the water ligands were shown to be quite labile, allowing for 
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substitution with tridentate ligands to form complexes with exceptional stability (>48 hours 
in serum). This opened the doors for the development of a wide range of methodologies 
for the incorporation of 99mTc into imaging probes (Figure 1.7).46–50 
 
Figure 1.7: 99mTc(I)-tricarbonyl complexes formed with a wide variety of ligands. 
Examples include tridentate ligands such as the amino acid histidine, cyclopentadienyl 
ligands coordinated in an h3 fashion, and [2+1] systems where a bidentate and monodentate 
ligand occupy the 3 coordination sites. 
The high stability and facial orientation of the carbonyl ligands can be attributed to the 
two-component bonding of the ligand to the metal center (Figure 1.8). The first component 
is a simple sigma bond where the electrons in the sp-orbital of the carbon atom of the triple 
bonded carbonyl ligand is donated to a vacant d-orbital on the metal. The second 
component is a p back-bond. The partially filled d-orbital of the metal center can donate 
electron density to the empty p* orbital of the carbonyl ligand. While this decreases the 
CO bond order, the metal-CO bond order is increased, resulting in a strong metal-ligand 
bond. The facial orientation results from the orientation of the d-orbitals that are back-
bonding to the carbonyl ligands. 
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Figure 1.8: Two-component binding of a carbonyl ligand to a metal center. 
1.5 Rhenium 
As described in the previous section, the chemistry of technetium is vast, with a variety of 
oxidation states and ligands available. The development of 99mTc-labelled 
radiopharmaceuticals can be challenging, as technetium has no stable isotopes. While 
technetium-99 complexes may be produced on milligram to gram scales to study the 
macroscopic properties of the technetium-99m complexes, the radioactive nature of the 
isotope limits its availability and use. A more common approach is to use the non-
radioactive rhenium as a surrogate for technetium. As both are group VII elements, they 
share similar chemical reactivity, and tend to form isostructural complexes with similar 
physicochemical properties such as size and lipophilicity.51 This allows not only for 
structural characterization of the metal complexes by standard spectroscopic methods such 
as X-ray crystallography and infrared spectroscopy, but also allows for in vitro evaluation 
of 99mTc radiopharmaceuticals for their ability to bind a molecular target without the use 
of radioactive material. Rhenium exists in nature as a mixture of two isotopes, 185Re (37%) 
and 187Re (63%). Radioactive isotopes of rhenium 186Re and 188Re undergo b- decay, and 
have seen clinical use as radiotherapeutics.52,53 
Though rhenium has seen wide use as a surrogate for technetium-99m in the development 
of radiopharmaceuticals, rhenium complexes are also useful in other aspects. Many Re(I)-
tricarbonyl complexes display photoluminescence properties and have been developed as 
cellular imaging agents for microscopy applications (Figure 1.9).48,49,54–56 While these 
photoluminescence properties generally result from metal-to-ligand charge transfer 
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(MLCT) electronic transitions, complexation to rhenium has also been shown to modulate 
the fluorescence properties of fluorophores adjacent to the metal complex.57,58 
Luminescent Re(I)-tricarbonyl complexes typically have large Stokes shifts, long 
luminescent lifetimes, high photostability and high cellular permeability, making them 
ideal imaging agents for cellular microscopy. They also have the potential to aid in the 
preclinical development of 99mTc radiopharmaceuticals by allowing the visualization of 
tissue uptake and cellular localization of targeted imaging agents without the need for using 
radioactive isotopes. They may also be helpful in the analysis of ex vivo tissue samples for 
studying and diagnosing disease. 
 
Figure 1.9: Examples of luminescent Re(I)-tricarbonyl complexes with p-accepting 
polypyridyl ligands. Suitable ligands include 2,2’-bipyridine, phenanthroline, quinoline 
and phenanthrodine. 
1.6 C-X-C Chemokine Receptor 4 
The C-X-C chemokine receptor 4 (CXCR4, also called LESTR or Fusin), a G protein-
coupled receptor (GPCR), was originally discovered as a co-receptor to CD4 for HIV-1 
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infection into T-lymphocytes.59–63 In addition to T-lymphocytes, it was also shown to be 
expressed on B-cells and monocytes.60 The only known natural ligand to CXCR4, stromal 
cell-derived factor 1 (SDF-1a, also called CXCL12) has been shown to support the 
proliferation of B-cells64 and is a strong chemoattractant for lymphocytes and monocytes, 
due to the interaction of SDF-1a with CXCR4.65 Together, CXCR4 and SDF-1a also play 
a role in the recruitment of T-lymphocytes to sites of infection and inflammation within 
the body,66,67 hematopoiesis,68 and embryonic development.69 In recent years, there has 
been a surge in research on CXCR4/SDF-1a focusing on their role in cancer. CXCR4 is 
expressed in at least 23 different types of cancer including breast, prostate, lung, colon, 
glioma and multiple myeloma.70–77 Expression of CXCR4 in cancers has been shown to 
promote metastasis,78–81 particularly to sites containing high expression of SDF-1a such as 
lymph nodes, bone marrow, lungs and liver.71,82–85 Most healthy tissues contain very low 
expression of CXCR4, but in cancerous tissue the expression is greatly enhanced. It may 
also be noted, that while prostate cancer tissue overexpresses CXCR4, expression remains 
low in benign prostatic hyperplasia (BPH) and healthy prostate tissue.86 This provides a 
diagnostic biomarker that may be used to differentiate healthy and benign tissue from 
malignant. The roles of CXCR4/SDF-1a in diseases such as cancer and HIV prompted the 
development of inhibitors as therapeutics and molecular imaging agents for evaluation of 
CXCR4 expression in vivo. 
A turning point in the development of CXCR4 inhibitors occurred upon the discovery of 
the antimicrobial self-defense peptides tachyplesin I & II and polyphemusin I & II from 
the hemocytes of the horseshoe crabs Tachypleus tridentatus and Limulus polyphemus.87,88 
These peptides are structurally intriguing as they contain 17 or 18 amino acids for 
tachyplesin and polyphemusin respectively, an amidated C-terminus, and two disulfide 
bridges stabilizing an anti-parallel b-sheet structure. Not only did these peptides 
demonstrate antimicrobial activity, but were also shown to inhibit the infectivity of HIV-1 
into MT-4 cells.89 Though they were effective at inhibiting HIV-1 infection, they were also 
found to be relatively cytotoxic. As polyphemusin II was shown to have the greatest 
inhibitory effect on HIV, it was used as a scaffold to reduce cytotoxic effects and improve 
potency, which led to the development of the peptide T22 ([Tyr5,12, Lys7]-polyphemusin 
15 
 
II), which had much greater potency, and reduced cytotoxicity.90,91 It wasn’t until 5 years 
after the development of T22 that it was discovered the inhibitory effect on HIV was due 
to the peptide’s interaction with CXCR4.92 Further efforts to reduce the molecular size of 
the peptide while retaining high potency and low cytotoxicity resulted in the peptide TW70, 
which reduced the size of the peptide to 14 amino acids, and removed one of the disulfide 
bridges while retaining the b-sheet structure and potency, and reducing cytotoxicity.93 It 
was observed that cell membrane permeability and the number of positive charges had a 
great effect on the selectivity index (SI, ratio of cytotoxicity measure (CC50) to potency 
(EC50)), resulting in the peptides T134, and finally T140, which replaced the amidated C-
terminus with a carboxylic acid, and reduced the charge of the molecule to +7, giving the 
highest SI values thus far.94,95 Figure 1.10 highlights the structural changes made from 
polyphemusin II to T140. 
 
Figure 1.10: The development of T140 from polyphemusin II. Black bars indicate 
disulfide bridges (top bars pertain to polyphemusin II and T22, bottom bar pertains to 
TW70, T134 and T140), colours indicate structural changes made in the subsequent 
peptide. 
Alanine scans of T140 determined that there were 4 residues that were indispensable to the 
binding affinity of the peptide to CXCR4: Arg2, Nal3, Tyr5 and Arg14.95 This eventually led 
to the development of the cyclic pentapeptide FC131 (cyclo[Nal1-Gly2-D-Tyr3-Arg4-
Arg5]), which retained similar affinity for CXCR4 as T140.96  
Small molecule CXCR4 inhibitors have also been developed separately from the peptide 
inhibitors. It was noticed that molecules containing two cyclam rings (bicyclams) were 
able to inhibit HIV infection in human T cells with varying potencies, without any 
noticeable cytotoxic effects.97 It was eventually determined that a p-xylylene spacer linking 
the two cyclam rings gave the compound with the highest potency out of all of the 
synthesized analogues, and was denoted JM3100.98 This compound now goes by the name 
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AMD3100 or Plerixafor, and it has been shown to inhibit HIV infection through interaction 
with CXCR4.99 AMD3100 has also seen clinical use as a mobilizer of hematopoietic stem 
cells.100 Figure 1.11 depicts the structures of the described CXCR4 inhibitors T140, FC131 
and AMD3100. 
 
Figure 1.11: Peptide (T140, FC131) and small molecule (AMD3100) inhibitors of 
CXCR4. 
While CXCR4 inhibitors show great promise as therapeutics for HIV, they have also shown 
potential as anti-metastatic agents in several cancers.101,102 The ability to target CXCR4 in 
cancer has garnered much interest in developing molecular imaging agents containing 
radioactive and fluorescent tags for evaluation of CXCR4 expression both in tissue 
samples, and in vivo. As healthy tissue surrounding the diseased site does not express high 
amounts of CXCR4, the diseased tissue may be specifically targeted by molecular imaging 
agents. Figure 1.12 depicts the structures of several radiolabelled molecular imaging agents 
targeting CXCR4. A wide range of T140 derivatives have been developed containing 
imaging labels. These labels are typically placed on the peptide’s N-terminus, or from the 
D-Lys side chain. It has been demonstrated that the turn region lies outside of the CXCR4 
binding pocket, making the D-Lys side chain ideal for conjugation of an imaging moiety.103 
Amidation of the N-terminus has also been shown to have little effect on binding affinity, 
often improving it, though bulky substituents may have negative effects on receptor 
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binding. The first reported PET imaging agent based on the T140 scaffold was [18F]4-FB-
TN14003 (Figure 1.12, Top Right).104 This peptide contains an [18F]4-fluorobenzoyl 
([18F]4-FB) group on the N-terminus, which improved CXCR4 affinity for the receptor. 
However, addition of the 4-FB group had the unwanted side effect of causing non-specific 
binding to red blood cells, which made targeting CXCR4 expressing tumors rather 
challenging in vivo. Inclusion of a non-radioactive, fluorine-19 containing N-terminal 4-
FB group in other radiolabelled T140 derivatives showed similarly high blood uptake in in 
vivo animal models.105 Several other radiolabelled T140 derivatives have mitigated the 
problem of binding to blood cells, but often give poor tumor uptake or high accumulation 
in the liver and kidneys.106–108 Despite the shortcomings of these agents, a 68Ga-labelled 
T140 derivative has been tested for imaging of CXCR4 expression in glioma patients.109 
This imaging agent showed specific uptake of the tracer in the cancerous tissue, with a 
much lower background signal in comparison to [18F]FDG. Fluorescently labelled T140 
derivatives have been used successfully as an alternative to antibody staining to evaluate 
CXCR4 expression in Ewing sarcoma110 and high-grade bladder cancer.111 
 
Figure 1.12: PET and SPECT molecular imaging agents targeting CXCR4. 
Structure-activity relationship studies on FC131 led to the development of the Pentixafor 
(previously named CPCR4-2) scaffold (Figure 1.12).112,113 Coordination of Ga(III) to the  
appended DOTA chelator resulted in an imaging probe with similar affinity to CXCR4 as 
FC131. The 68Ga-labelled peptide has been used in humans for imaging of CXCR4 
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expression in a wide variety of cancers, and has great promise as a clinically useful PET 
imaging agent.15,114,115 Several other derivatives of Pentixafor have been explored in in 
vitro models, and also show promise for in vivo imaging as well as radiotherapy.116–119 It 
was previously demonstrated that coordination of AMD3100 with metal ions such as 
Cu(II), Zn(II) and Ni(II) improved the binding affinity of the molecule to CXCR4.120 This 
concept has been used in the development of radiolabelled AMD3100 analogues. 
[64Cu]Cu-AMD3100 was used to successfully differentiate CXCR4-positive tumors in an 
in vivo animal model.121,122 99mTc-labelled AMD3100, and the derivative AMD3465 have 
also shown promise as SPECT imaging agents for imaging of CXCR4 expressing tumors 
in vivo.123,124 
Targeting of the CXCR4/SDF-1a axis for therapeutic and diagnostic purposes in HIV and 
cancer is a large and rapidly growing field. Despite all of the work in the field, the need for 
imaging agents with improved pharmacokinetic and biodistribution profiles is still an area 
of research that is actively being developed. While radiolabelled agents targeting CXCR4 
are being evaluated in humans for PET imaging, there is still a need for imaging agents 
compatible with SPECT imaging, as well as PET agents with improved pharmacokinetics. 
1.7 Biological Roles of Zinc 
Zinc is a ubiquitous element in the human body. It is the second most abundant transition 
metal, second only to iron. Under physiological conditions, zinc is found in the form of 
Zn(II). While total zinc concentration in cells is in the mM range, free zinc concentrations 
are tightly regulated. This is achieved through active transport by the zinc transporter (ZnT) 
and zrt-like, irt-like protein (ZIP) classes of transporters,125 buffering of zinc by 
metallothioneins,126 and sequestering of zinc into organelles such as zincosomes.127,128 This 
results in free zinc concentrations in the nM range.129 
Zinc has a broad range of cellular functions and roles (Figure 1.13). Zn(II) ions function as 
co-factors for a number of zinc-dependent enzymes.130–132 Enzymes such as carbonic 
anhydrase,133 carboxypeptidase A,134 and alkaline phosphatase135 require the Zn(II) ion to 
activate electrophilic sites so that enzymatic hydrolysis can occur. Zn(II) ions act as 
structural elements of many proteins such as zinc finger transcription factors.136 Insulin is 
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also stored as a hexamer through coordination with Zn(II),137 and metal ions such as Zn(II) 
and Cu(II) have been implicated in the formation of amyloid plaques in Alzheimer’s 
disease.138 Zn(II) signaling plays a key role in neurotransmission,139,140 as well as the 
activation and inhibition of transcription factors.141 Disruption of the tightly regulated zinc 
homeostasis has been implicated in a number of diseases such as diabetes,142 Alzheimer’s 
disease138 and prostate cancer.143 The following section will discuss the role of zinc in the 
latter. 
 
Figure 1.13: Biological distribution and functions of zinc. Abbreviations: IAP, inhibitor 
of apoptosis protein; ROS, reactive oxygen species; ER, endoplasmic reticulum; ZIP, Zrt-
like, Irt-like protein; ZnT, zinc transporter. 
1.7.1 Zinc in Prostate Cancer 
It was documented as early as the 1920s that the human prostate has the highest zinc 
concentration of any soft tissue (~1000 µg/g of dry tissue),144 though the exact reason for 
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this is not entirely clear. It has been noted that prostate epithelial cells have 
characteristically high aerobic glycolysis, low respiration rates, and high citrate secretion, 
and it has been proposed that high zinc concentrations are required to maintain these 
characteristics.145,146 Zinc was shown to inhibit m-aconitase, an enzyme responsible for 
citrate oxidation, which may be responsible for the high citrate secretion and low 
respiration in prostate tissue.147,148 It has also been demonstrated that in malignant prostate 
tissue there is a nearly ten-fold reduction in zinc concentration.149 Decreases in cellular 
zinc may lead to an increase in cellular respiration favouring growth and differentiation, 
which may lead to malignancy.150 Zinc has also been shown to regulate apoptosis in 
prostate cells.151 Lower levels of zinc can be attributed to an increase in the expression of 
ZnT proteins, responsible for zinc export, and a decrease in the expression of ZIP proteins, 
which are responsible for zinc import.152 Also to be noted, benign hyperplastic prostate 
tissue retains the high zinc accumulation observed in healthy prostate tissue.149  
Due to the characteristic decrease in zinc concentration in malignant prostate tissue, there 
has been much clinical interest in zinc as a biomarker for prostate cancer, allowing for the 
differentiation of malignant prostate tissue from benign and healthy. Evaluation of prostatic 
zinc levels has mostly been limited to ex vivo analysis of biopsies through a variety of 
methods.153–155 More recently, the development of molecular imaging agents for in vivo 
analysis of prostatic zinc levels has been investigated.156 However, for the pre-clinical 
study of zinc as it relates to disease, the development of fluorescent, cell permeable 
indicators for zinc has been a large area of investigation.157,158 The following section will 
discuss the mechanisms behind the function of zinc-sensitive fluorescent probes. 
1.7.2 Fluorescent Probes Responsive to Zinc 
The detection of zinc by spectroscopic methods can be challenging, as the 3d10 electron 
configuration makes the metal ion alone insensitive to spectroscopic methods such as NMR 
and UV/Vis. However, ligand-centric photophysical processes may be exploited as a 
method of fluorescence detection of Zn(II). Quantum yields, fluorescence lifetimes, and 
excitation/emission energies of a ligand/fluorophore can be manipulated by coordination 
to Zn(II). The appropriate choice of chelator and fluorophore that imparts selectivity to 
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Zn(II) over other metal ions would give a fluorescent probe with a signal unique to the 
presence of Zn(II).  
Fluorescent stains for biological zinc began gaining wide acceptance in the 1980s with 
histochemical stains based on 8-aminoquinoline such as N-(6-methoxyquinolin-8-yl)-p-
toluenesulfonamide (TSQ).159 Further research has focused on improving cellular 
permeability160 and shifting excitation and emission wavelengths further into the visible 
range (Figure 1.14).161 
 
Figure 1.14: Evolution of zinc responsive fluorescent probes: TSQ, to the more cell 
membrane permeable ZnAF-R2, and the visible light excitable FluoZin-1, and the cell 
membrane permeable variant FluoZin-1 AM. 
A variety of ligand-centric photophysical processes have been exploited in the 
development of zinc-responsive fluorescent probes. These include: photoinduced electron 
transfer (PeT), intramolecular charge transfer (ICT), excited-state intramolecular proton 
transfer (ESIPT), Förster resonance energy transfer (FRET), and excimer/exciplex 
formation. In this section, PeT, ICT and ESIPT will be discussed in further detail. 
Photoinduced electron transfer (PeT, not to be confused with positron emission 
tomography (PET)) is a fluorescence quenching mechanism that occurs in molecules 
containing a fluorophore that is appended with an electron donor. Note that there is no 
conjugated p-system involved (i.e. there is no ground state mixing of the respective 
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molecular orbitals). Upon promotion of the fluorophore to the excited state, the electron 
donor may donate an electron into the half-filled HOMO of the fluorophore (a redox 
process), affording a radical cation/anion pair. This prevents the electron located in the 
LUMO of the fluorophore from returning to the ground state, effectively quenching 
fluorescence emission. As PeT applies to Zn(II) indicators, the electron donor is typically 
a chelating moiety, capable of selectively binding to Zn(II). Chelators containing tertiary 
amino groups are often employed due to their oxidizable nature. The HOMO of the chelator 
is of a higher energy than that of the fluorophore, allowing for donation of an electron from 
the chelator to the fluorophore. In the free ligand state, fluorescence is efficiently quenched 
(Figure 1.15, Top). 
However, coordination of the chelating moiety to Zn(II) lowers the HOMO energy of the 
electron donor, preventing electron transfer to the excited state fluorophore HOMO. This 
restores the fluorescence emission pathway (Figure 1.15, Bottom). PeT sensors are 
therefore “turn-on” sensors. Coordination to Zn(II) typically causes little change in the 
excitation and emission energies, but an increase in fluorescence quantum yield (ff) is 
observed. The fluorescence intensity may then be correlated to the concentration of Zn(II). 
FluoZin-1 (Figure 1.14, right) is an example of a Zn(II) indicator operating by a PeT 
mechanism. 
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Figure 1.15: The process of PeT as applied to Zn(II) indicators. Coordination of Zn(II) 
prevents the metal chelator from acting as an electron donor, increasing fluorescence 
intensity from the fluorophore. 
In contrast to PeT where an electron donor and acceptor are separated, ICT fluorophores 
contain a p-conjugated electron donor and acceptor. Upon photoexcitation, charge 
separation occurs in the fluorophore, resulting in a polar excited state. Fluorophores 
displaying ICT characteristics are positively solvatochromic in nature (i.e. excitation and 
emission energies decrease with increasing solvent polarity). In non-polar solvents, a 
“locally excited” state occurs in which the excited fluorophore has little effect on solvent 
ordering. In polar solvents, the solvent molecules may align their dipoles with the dipole 
of the excited fluorophore, effectively decreasing the energy of the excited state, and 
shifting the fluorescence emission wavelength further into the visible range (Figure 1.16, 
Top).162  
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Figure 1.16: ICT mechanism in non-polar and polar solvents (top), and upon coordination 
to Zn(II) (bottom). 
In the case of the zinc indicator ZnAF-R2 (Figure 1.14, middle) where Zn(II) binds to the 
electron donor site, the ability of the donor to transfer electron density to the acceptor is 
reduced and the excited state is destabilized, which hypsochromically shifts the excitation 
and emission wavelengths. However, coordination of Zn(II) to the acceptor site, as is the 
case in many 2,2’-bipyridine based zinc indicators, results in a stabilization and a decrease 
in polarity of the excited state due to the cationic Zn(II) (Figure 1.16, Bottom). As a result, 
a bathochromic shift in the excitation and emission wavelengths occurs. As the free ligand 
and the Zn(II) complex will typically display fluorescence, in theory the ratio of the 
fluorescence emission from the ligand and the Zn(II) complex may be used to determine 
Zn(II) concentrations. This is usually not done in practice however, as the absorption 
wavelengths of the free ligands often occur in the UV range, and are not ideal for use in 
live cells and tissues. 
ESIPT occurs in molecules where intramolecular hydrogen bonds are present, and 
tautomerization is possible.163 Phototautomerization may occur in the excited state of a 
molecule, with a concomitant transfer of a proton from a photoacid to a photobase. 2-(2’-
Hydroxyphenyl)benzoxazole (HBO) is an example of an ESIPT fluorophore (Figure 1.17). 
In non-polar solvents, ESIPT occurs at a faster rate than fluorescence emission. Therefore, 
the lower energy emission from the phototautomeric form dominates. As solvent polarity 
increases, the rate of proton transfer decreases due to hydrogen bonding with the solvent, 
and the emission from the phototautomer decreases. If the photobasic and photoacidic sites 
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become coordinated to a metal ion such as Zn(II), ESIPT is no longer possible (Figure 1.17, 
Left). The emission energy becomes intermediate between the energies of the 
phototautomeric forms. As with ICT fluorophores, the ratio between emission from the 
free ligand and the metal complex may be used to determine Zn(II) concentrations. 
 
Figure 1.17: Process of ESIPT occurring in HBO, and Zn(II) coordination suppressing 
ESIPT. 
While there is certainly a plethora of Zn(II) sensitive fluorescent probes to choose from, 
there is still plenty of room for advancement in the field. There is still a need to develop 
sensors with useful ratiometric fluorescence emission, so that the probe may be visualized 
in the free ligand, and Zn(II) coordinated states, improvement in cellular permeability and 
cellular localization as well as a lack of toxicity to the target cells or tissues that are being 
interrogated.164 
1.8 Summary 
This thesis will document the discovery of new metal chelators for Re/99mTc, new methods 
of incorporating these metals into peptide structures, as well as new fluorescent 
compounds. These novel methods and compounds may be used in the development of 
molecular imaging probes for SPECT and OI techniques, with applications for 
differentiating cancerous tissue from benign and healthy. Chapter 2 will discuss the 
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development of a dual modality Re/99mTc imaging probe for fluorescence/SPECT imaging 
derived from T140 for the evaluation of CXCR4 expression in cancer cells, with 
applications to differentiating malignant prostate cells from benign. Chapter 3 contains a 
study evaluating the fluorescence properties and radiolabelling of Re/99mTc-containing 4-
amino-1,8-naphthalimides towards tuning the pharmacokinetic and biodistribution 
properties of their bioconjugates. Chapter 4 highlights the challenges in developing 
integrated molecular imaging probes. The development of 3,3’-diamino-2,2’-bipyridine 
containing peptides as SPECT imaging agents will be discussed. Chapter 5 will discuss the 
development of amino-substituted 2,2’-bipyridine ligands as intracellular Zn(II) sensors, 
and their application in differentiating malignant and benign prostate cells by their 
differences in Zn(II) uptake. Chapter 6 will summarize the findings of the thesis and how 
they advance the field of molecular imaging as a whole. 
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Chapter 2 
2 A Dual Modality 99mTc/Re(I)-Labelled T140 Analogue for 
Imaging of CXCR4 Expression 
2.1 Introduction 
The C-X-C chemokine receptor 4 (CXCR4) and its natural ligand CXCL12 are involved 
in developmental, immune and inflammatory processes in healthy tissues.1,2 It was first 
discovered as a co-receptor for HIV infection into T lymphocytes.3–5 CXCR4 has been 
shown to be overexpressed in at least 23 types of cancer,6 including prostate cancer (PCa),7 
where it and CXCL12 are involved in metastasis,7–9 angiogenesis,10 and adhesion of PCa 
cells to bone marrow endothelial cells.11,12 While CXCR4 expression is higher in PCa and 
associated metastases, expression is low in benign prostatic hyperplasia and normal 
prostate tissue.13 This gives the potential for CXCR4 to be a biomarker to aid in the 
diagnosis of PCa and differentiating malignant and benign tissue. CXCR4 expression was 
shown to be a superior predictor of bone metastasis to the Gleason score, and that 94% of 
patients with metastatic prostate cancer showed expression of the protein. Patients with 
high CXCR4 expression had an overall lower cancer-specific survival than those with low 
expression of the receptor.8 Therefore, CXCR4 is a potential diagnostic and prognostic 
factor for prostate cancer. CXCR4 targeted imaging agents may aid in the visualization of 
metastatic lesions, and CXCR4 antagonists have therapeutic potential for metastatic 
prostate cancer. 
Several CXCR4 antagonists have been reported, including the biscyclam AMD3100,14 14 
amino-acid b-hairpin peptide T140,15 and cyclic pentapeptide FC131.16 These three 
compounds have been widely used as scaffolds for the development of positron emission 
tomography (PET), single photon emission computed tomography (SPECT), and 
fluorescence imaging probes targeting CXCR4, and several published reviews discuss this 
topic.17–19 While the development of CXCR4 targeted nuclear imaging probes has 
previously been focused on PET agents containing 68Ga, 64Cu and 18F, only a few SPECT 
imaging agents had been developed. Recently there has been a surge in the number of 
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publications on CXCR4 targeted SPECT imaging agents containing 99mTc as the 
radionuclide.20–23 
Multi-modality imaging agents are of great interest, as a single compound may be used for 
various clinical applications and can combine the advantages of different modalities, while 
mitigating some of the disadvantages.24–26 These agents typically contain a separate label 
for each modality (i.e. a radionuclide for PET/SPECT, and a fluorophore for fluorescence). 
This presents many design challenges, as fluorophores and metal chelators can be quite 
large in size and molecular weight. Conjugation of multiple large moieties to biomolecules 
such as peptides can have a negative impact on their ability to bind a biological target. For 
example, a dual-modality CXCR4 targeted imaging agent has previously been reported for 
dual SPECT/fluorescence imaging.27 The T140 analogue Ac-TZ14011 was derivatized 
with an 111In labelled diethylenetriaminepentaacetate (DTPA) chelator for SPECT imaging 
and a Cy5.5 dye for fluorescence imaging. Introduction of these large moieties resulted in 
a 20-fold reduction in binding affinity to CXCR4 due to increased steric bulk. Due to this 
decrease in binding affinity, it would therefore be advantageous to reduce the size of the 
appended labels by incorporating a fluorophore and radioisotope into a single, more 
compact entity.28 Rhenium(I) tricarbonyl complexes can exhibit fluorescence and replacing 
rhenium with technetium-99m would allow for single photon emission computed 
tomography (SPECT) imaging. 4-Amino-1,8-naphthalimides appended with a di-(2-
picolyl)amine binding unit coordinated to Re(I) have been reported as cellular imaging 
agents with ideal fluorescence properties.29 However, their incorporation into biological 
molecules and labelling with 99mTc has not been explored. 
Herein, we report the synthesis and evaluation of a dual modality imaging agent derived 
from T140 containing a 4-amino-1,8-naphthalimide appended with a di-(2-picolyl)amine 
(DPA) binding unit (Figure 2.1). The peptide was coordinated to Re(I) for evaluation of 
CXCR4 binding and photophysical properties. CXCR4 expression in various cell lines, 
including prostate cell lines, was observed by confocal fluorescence microscopy. Labelling 
with 99mTc(I) was performed for evaluation in a murine xenograft model. 
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Figure 2.18:  Structure of T140 (6) and the newly synthesized derivative DPA-Naph-
T140 (7). 
2.2 Results and Discussion 
2.2.1 Design and Synthesis 
A carboxylic acid functionalized dipicolylamine-naphthalimide (DPA-Naph) fluorophore 
(5) was synthesized in five steps from commercially available 4-chloro-1,8-naphthalic 
anhydride (scheme 2.1) and conjugated to T140 through solid-phase peptide synthesis. 
Naphthalimide 1 was synthesized by reacting 4-chloro-1,8-naphthalic anhydride and ethyl 
3-aminopropionate in refluxing ethanol. This was then heated in DMSO with tert-butyl (2-
aminoethyl)carbamate giving the Boc-protected amine 2. Deprotection of the Boc group 
with TFA yielded the free amine 3, which underwent reductive alkylation with 2-
pyridinecarboxaldehyde to form the tridentate chelator 4. Saponification of the ethyl ester 
gave the carboxylic acid 5 (DPA-Naph-OH), which could then be conjugated to a peptide 
by standard peptide coupling methods.  
39 
 
 
Scheme 2.1: Synthesis of compound 5 (DPA-Naph-OH). 
The D-Lys8 side chain of T140 was chosen as the site of conjugation, as previous reports 
show that this residue is located outside of the CXCR4 binding pocket.30 Peptides were 
synthesized by standard Fmoc solid-phase peptide synthesis techniques. The D-Lys8 side 
chain was protected with an allyloxycarbonyl (Alloc) protecting group for selective 
deprotection and coupling of 5. Compound 5 was conjugated to the peptide through 
standard HCTU coupling procedures. After disulfide bridge formation by oxidation with I2 
and final Fmoc deprotection, the peptide was cleaved from the resin and purified by 
preparative HPLC-MS to give the peptide with the free chelator (7). We then synthesized 
the rhenium tricarbonyl complex, by reacting the peptide with [Re(H2O)3(CO)3]OTf under 
microwave conditions. The peptide was then purified by preparative HPLC-MS to give the 
peptide Re-7. UV/Vis absorption and fluorescence data are summarized in Table 2.1. 
Reported values are very similar to those given by Pope et al. for the four rhenium 
naphthalimides they had synthesized, confirming that the fluorophore retains its 
fluorescent properties upon conjugation to a peptide, and subjected to aqueous conditions. 
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Table 2.1: Photophysical Properties of DPA-Naph Peptide Conjugates. 
Peptide almax e (M-1cm-1) lem bff 
7 450 nm 14,100 545 nm 0.28 
Re-7 439 nm 12,370 527 nm 0.70 
a18 µM in H2O. bRelative to [Ru(bpy)3](PF6)2 in aerated H2O (ff = 0.04) 
2.2.2 In Vitro Evaluation of Re-7 
To investigate the influence of the DPA-Naph moiety and metal complex on the peptide’s 
ability to bind to CXCR4, competitive binding assays were performed using stably 
transfected U87.CD4.CXCR4 cells with [125I]-SDF-1 as the competing ligand. Under our 
assay conditions, the parent peptide T140 (6) gave an IC50 value of 1.0 nM, while Re-7 
only showed a modest increase in IC50 to 1.9 nM (Figure 2.2). This indicates that 
conjugation of the DPA-Naph moiety, and formation of the rhenium tricarbonyl complex 
has little influence on the ability of the peptide to bind the receptor, as the D-Lys8 side chain 
is located outside of the CXCR4 binding pocket. 
 
Figure 2.19: Representative competitive binding curves of T140 (black curve) and Re-7 
(grey curve) using U87.CD4.CXCR4 cells with [125I]-SDF-1 as the competing radioligand. 
Confocal fluorescence microscopy was then performed to validate Re-7 as a fluorescent 
imaging agent specific for CXCR4. U87.CD4.CXCR4 and U87.CD4 cells were incubated 
with Re-7 and were then fixed and mounted on slides for imaging. U87.CD4.CXCR4 cells 
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showed strong fluorescence, while U87.CD4 cells did not (Figure 2.3), indicating that Re-
7 can selectively detect CXCR4 in cells expressing the receptor.  
 
Figure 2.20: Confocal microscope images of U87.CD4.CXCR4 cells (A, C) and U87.CD4 
cells (B, D) incubated with Re-7. lEx = 458 nm, lEm = 500-550 nm, 40x objective. 
It has been previously reported in the literature that PCa cell lines such as PC-3 and DU 
145 express CXCR4 to a much higher extent than benign prostate cells such as BPH-1.13 
These three cell lines were also incubated with Re-7 and observed by confocal microscopy 
to evaluate CXCR4 expression (Figure 2.4). BPH-1 cells showed no discernable 
fluorescence. Both PC-3 and DU 145 cells however, displayed observable fluorescence. 
The fluorescence intensity was not as strong as that seen in U87.CD4.CXCR4 cells due to 
the endogenous expression of CXCR4 being lower in the PCa cells than in the transfected 
cells. As CXCR4 expression was observable in the PCa cells and not in the BPH cells, Re-
7 may be useful in ex vivo analysis of prostate tissue to differentiate benign and malignant 
prostate tissue by their CXCR4 expression. 
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Figure 2.21: Confocal microscope images of BPH-1 (A, D), PC-3 (B, E) and DU 145 cells 
(C, F) incubated with Re-7. lEx = 458 nm, lEm = 500-550 nm, 40x objective. 
2.2.3 99mTc-labelling and In Vitro Cellular Uptake 
Peptide 7 was also radiolabelled with 99mTc to give [99mTc]Tc-7. The peptide was labelled 
by reaction with [99mTc]Tc(CO)3(H2O)3+ under microwave conditions. The radiolabelled 
peptide was purified by semi-preparative HPLC, giving decay corrected radiochemical 
yields ranging from 60-85%, radiochemical purities of >95% (Figure 2.5, left) and molar 
activities of 36-44 GBq/µmol.  
Cellular uptake of [99mTc]Tc-7 was evaluated in U87.CD4.CXCR4 cells in comparison to 
U87.CD4 cells (Figure 2.5, right). Approximately two-fold higher uptake was observed in 
the CXCR4 expressing cells (10.4 ± 0.8%) compared to the U87.CD4 cells (5.6 ± 0.1%). 
While there was a relatively high amount of non-specific binding observed as seen by the 
high uptake in U87.CD4 cells, the radiolabelled peptide shows specific uptake in CXCR4 
expressing cells. 
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Figure 2.22: (Left) UV-HPLC chromatogram of Re-7 (blue) overlaid with the radio-HPLC 
chromatogram of [99mTc]Tc-7 (black). (Right) In vitro cellular uptake of [99mTc]Tc-7 in 
U87.CD4.CXCR4 cells in comparison to U87.CD4 cells. 
2.2.4 Ex Vivo Biodistribution Studies 
Ex vivo biodistribution studies were performed with [99mTc]Tc-7 in NOD/SCID mice 
bearing U87.CD4.CXCR4 tumors. The animals were sacrificed at 2 hours post-injection, 
and the activity was determined in the organs of interest (Figure 2.6). Uptake in the liver 
and kidneys was quite high (22.67 ± 5.02 and 25.69 ± 15.19 % ID/g respectively), which 
is consistent with several other radiolabelled T140 derivatives due to hepatic metabolism 
and urinary clearance.27,31,32 Moderate uptake was also observed in the lung, spleen, 
intestines and stomach. The stomach is known to express CXCR4 to a small degree,33 so 
this may account for some of the uptake. However, previous reports also suggest that 
hydrophobic imaging labels may increase non-specific uptake in undesired tissues,34 
including the stomach.27 Therefore, the uptake may be non-specific, driven by the relatively 
non-polar naphthalimide metal complex. The lung, spleen and intestinal uptake is likely 
caused by specific binding to CXCR4, as these organs are known to have moderate 
expression of the receptor,22 and previously reported CXCR4-targeted radiotracers are 
known to specifically accumulate in these organs. Disappointingly, tumor uptake was quite 
low (0.51 ± 0.09 % ID/g). This may be due to a combination of higher blood uptake (1.91 
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± 0.16 % ID/g) compared to many other T140-based radiotracers along with specific 
accumulation in other organs. Optimization of the biodistribution of the peptide is required 
to improve the tumor uptake. Several T140 derived peptides have been reported that retain 
affinity for CXCR4 such as TN14003 and Ac-TZ14011, so exploration of other derivatives 
may help to improve the biodistribution. Alteration of the structure of the metal chelator to 
reduce lipophilicity may also lead to a peptide with an improved biodistribution and 
pharmacokinetic profile. 
 
Figure 2.23: Ex vivo biodistribution of [99mTc]Tc-7 in U87.CD4.CXCR4 tumor bearing 
mice at 2 hours post-injection (n = 3).  
2.3 Conclusions 
In summary, we have developed a novel T140 derivative (7) containing a 4-amino-1,8-
naphthalimide appended with a di-(2-picolyl)amine (DPA) binding unit to chelate Re(I)-
tricarbonyl for use in confocal fluorescence microscopy, and 99mTc(I)-tricarbonyl for use 
as a SPECT imaging agent. Re-7 showed specific uptake in U87.CD4.CXCR4 cells, as 
well as PC-3 and DU 145 PCa cells, while minimal uptake was observed in U87.CD4 and 
BPH-1 cells. This fluorescent peptide may be useful in differentiating malignant tissue 
from healthy and benign, as malignant tissue tends to express CXCR4 to a much higher 
extent. The technetium-99m labelled variant [99mTc]Tc-7 was prepared in high yield, purity 
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and molar activity, and was shown to have two-fold higher uptake in CXCR4 expressing 
cells. However, in a murine xenograft model, [99mTc]Tc-7 showed very low uptake in 
CXCR4 expressing tumors. Alteration of the metal chelation system appended to the 
naphthalimide to one with lower lipophilicity may provide a SPECT imaging agent with 
improved biodistribution. 
2.4 Experimental 
2.4.1 General Experimental 
All reagents were purchased from commercial sources and used without further 
purification. [Re(H2O)3(CO)3]OTf was synthesized according to a published procedure.35 
NMR spectra were recorded on a Bruker AvIII HD 400 spectrometer. All chemical shifts 
are reported in ppm and referenced to the residual solvent peaks. High resolution mass 
spectra for small molecules were recorded on a Waters Xevo QToF mass spectrometer with 
an electrospray ion source in positive mode. For peptides, high resolution mass spectra 
were recorded on a Bruker micrOTOF II mass spectrometer with an electrospray ion source 
in positive mode. Analytical reversed-phase HPLC-MS was performed on a system 
consisting of an Agilent Zorbax SB-C18 column (5 µm, 4.6 x 150 mm), Waters 600 
controller and Binary Solvent Pump, Waters Inline degasser, Waters Quattro Micro API 
mass spectrometer and Waters Mass Lynx software. Mass spectra were collected using an 
ESI source in positive ion mode. The gradient solvent system comprised of solvent A 
(CH3CN + 0.1 % TFA) and solvent B (H2O + 0.1 % TFA) at a flow rate of 1.5 mL/min 
over 10 minutes with a 5-minute wash cycle at 95% solvent A. The UV absorbance was 
detected using a Waters 2998 Photodiode array detector. Peptides were purified by 
reversed-phase preparative HPLC-MS on the same system with an Agilent Zorbax PrepHT 
SB-C18 column (5 µm, 21.2 x 150 mm) at a flow rate of 20 mL/min. After purification, 
the collected fractions were frozen at -78 °C, and lyophilized. Analytical radio-HPLC was 
performed on a system comprising of an Agilent Zorbax SB-C18 column (5 µm, 4.6 x 150 
mm), Waters 600 controller and Binary Solvent Pump, Waters Inline degasser with a 
Carroll & Ramsey radiometric detector connected to a waters e-Sat/IN module and Waters 
2498 dual absorbance UV-Vis detector. The gradient solvent system comprised of solvent 
A (CH3CN + 0.1 % TFA) and solvent B (H2O + 0.1 % TFA) at a flow rate of 1.5 mL/min 
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over 10 minutes with a 5-minute wash cycle at 95% solvent A. Semi-preparative radio-
HPLC was performed on the same system with an Agilent Zorbax SB-C18 column (3.5 
µm, 4.6 mm x 150 mm) at a flow rate of 4 mL/min. UV-Vis spectra were recorded on an 
Agilent Cary 60 UV-Vis spectrophotometer. Fluorescence spectra were recorded on a 
Photon Technologies International, Inc. Quanta Master – 7/2005. Quantum yields were 
determined in aerated H2O solutions of the peptides using [Ru(bpy)3](PF6)2 in H2O (f = 
0.04) as a standard.36 
 
Ethyl 3-(6-chloro-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propanoate (1) 
Triethylamine (1.8 mL, 12.9 mmol) and 4-chloro-1,8-naphthalic anhydride (2.00 g, 8.6 
mmol) were added to a solution of b-alanine ethyl ester hydrochloride (2.00 g, 12.9 mmol) 
in ethanol (80 mL). The resulting orange suspension was heated to reflux for 16 hours, 
which became a clear orange solution upon heating. The solution was cooled to room 
temperature, resulting in precipitation of the product as bright yellow needles, which were 
collected by filtration, washed with cold ethanol and diethyl ether and dried in vacuo. 
Yield: 2.17 g, 6.53 mmol, 76%. 1H NMR (CDCl3, 400 MHz) δ 8.65 (d, J = 7.1 Hz, 1H), 
8.59 (d, J = 8.5 Hz, 1H), 8.49 (d, J = 7.9 Hz, 1H), 7.83 (m, 2H), 4.48 (t, J = 7.4 Hz, 2H), 
4.14 (q, J = 7.1 Hz, 2H), 2.75 (t, J = 7.4 Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H) ppm. 13C NMR 
(CDCl3, 100 MHz) δ 171.2, 163.6, 163.3, 139.2, 132.1, 131.2, 130.8, 129.3, 129.1, 127.9, 
127.4, 122.9, 121.4, 60.7, 36.3, 32.7, 14.1 ppm. HR-MS (ESI+): m/z calculated for 
C17H15NO4Cl+ [M+H]+ 332.0690; found 332.0710. 
 
Ethyl 3-(6-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-1,3-dioxo-1H-
benzo[de]isoquinolin-2(3H)-yl)propanoate (2) 
To a suspension of 1 (1.5 g, 4.52 mmol) in DMSO (10 mL) was added tert-butyl (2-
aminoethyl)carbamate (2.17 g, 13.56 mmol), and the resulting suspension heated to 70 °C 
under a nitrogen atmosphere for 16 hours. The resulting orange suspension was cooled to 
room temperature and the pH adjusted to 6-7 with 0.1 M HCl. The resulting yellow 
precipitate was taken up into DCM, washed with water and brine, dried over MgSO4 and 
filtered. The orange solution was reduced to a minimum volume, and precipitation was 
induced by the addition of hexanes. The product was collected by filtration as an orange-
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yellow solid. Yield: 1.42 g, 3.12 mmol, 69%. 1H NMR (CDCl3, 400 MHz) δ 8.56 (d, J = 
7.5 Hz, 1H), 8.42 (d, J = 8.4 Hz, 1H), 8.26 (d, J = 8.4 Hz, 1H), 7.6 (t, J = 7.5 Hz, 1H), 7.08 
(br. s, 1H), 6.55, (d, J = 8.4 Hz, 1H), 5.13, (t, J = 6.1 Hz, 1H) 4.47 (t, J = 7.5 Hz, 2H), 4.14, 
(q, J = 7.1 Hz, 2H), 3.64 (m, 2H), 3.44 (m, 2H), 2.74 (t, J = 7.5 Hz, 2H), 1.47 (s, 9H), 1.22 
(t, J = 7.1 Hz, 3H) ppm. 13C NMR (CDCl3, 100 MHz) δ 171.6, 164.6, 164.0, 158.6, 150.3, 
134.7, 131.2, 129.9, 127.2, 124.7, 122.7, 120.4, 109.7, 103.3, 80.8, 60.6, 46.8, 39.5, 35.9, 
32.9, 29.7, 28.4, 14.2 ppm. HR-MS (ESI+): m/z calculated for C24H30N3O6 [M+H]+ 
456.2135; found 456.2123. 
 
Ethyl 3-(6-((2-aminoethyl)amino)-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-
yl)propanoate (3)  
Compound 2 (1.38 g) was dissolved in DCM (5 mL), followed by the addition of 
trifluoroacetic acid (5 mL), and stirred for 24 hours. The solvent was removed under 
reduced pressure. The resulting orange semi-solid was dissolved in water, the pH adjusted 
to 9 with 1 M NaOH, and extracted with DCM. The organic layer was washed with water 
and brine, dried over MgSO4, filtered and evaporated under reduced pressure to give the 
product as a yellow-orange solid. Yield: 0.60 g, 1.69 mmol, 56% 1H NMR (CDCl3, 400 
MHz) δ 8.51 (d, J = 7.3 Hz, 1H), 8.39 (d, J = 8.4 Hz, 1H), 8.14 (d, 1H, J = 8.3 Hz, 1H), 
7.56 (t, J = 7.9 Hz, 1H), 6.64 (d, J = 8.5 Hz, 1H), 6.22 (m, 1H), 4.46 (t, J = 7.5 Hz, 2H), 
4.14 (q, J = 7.1 Hz, 2H), 3.39 (dt, J = 5.1 Hz, 6.2 Hz, 2H), 3.17 (t, J = 6.2 Hz, 2H), 2.74 (t, 
J = 7.5 Hz, 2H), 1.46 (br. s, 2H), 1.22 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (CDCl3, 100 
MHz) δ 171.6, 164.5, 163.9, 149.8, 134.6, 131.2, 129.8, 126.4, 124.6, 122.8, 120.4, 109.9, 
104.4, 60.6, 44.9, 40.1, 35.9, 32.9, 14.2 ppm. HR-MS (ESI+): m/z calculated for 
C19H22N3O4 [M+H]+ 356.1610 found; 356.1669. 
 
Ethyl 3-(6-((2-(bis(pyridin-2-ylmethyl)amino)ethyl)amino)-1,3-dioxo-1H-
benzo[de]isoquinolin-2(3H)-yl)propanoate (DPA-Naph-OEt) (4) 
To a solution of 3 (0.55 g, 1.55 mmol) in 1,2-dichloroethane (20 mL) was added 2-
pyridinecarboxaldehyde (0.295 mL, 3.10 mmol), and the solution stirred for 2 hours under 
a nitrogen atmosphere. The solution was cooled to 0 °C on an ice-water bath, and sodium 
triacetoxyborohydride (0.75 g, 3.56 mmol) was added. The solution was allowed to warm 
48 
 
to RT, and then stirred for 48 hours. Water was added, and the product was extracted with 
chloroform. The organic layer was washed with water and brine, dried over MgSO4, 
filtered and concentrated to a minimum volume. The product was precipitated by the 
addition of hexanes and collected by filtration as a bright yellow solid. Yield: 0.65 g, 1.21 
mmol, 78%. 1H NMR (CDCl3, 400 MHz) δ 8.84 (d, J = 8.4 Hz, 1H), 8.63 (d, J = 7.3 Hz, 
1H), 8.59 (d, J = 4.6 Hz, 2H), 8.42 (d, J = 8.4 Hz, 1H), 7.93 (br. s, 1H), 7.70 (t, J = 7.8 Hz, 
1H), 7.58 (td, J = 7.7 Hz, 1.7 Hz, 2H), 7.39 (d, J = 7.8 Hz, 2H), 7.17 (dd, J = 7.8 Hz, 5.9 
Hz, 2H), 6.55 (d, J = 8.5 Hz, 1H), 4.5 (t, J = 7.6 Hz, 2H), 4.16, (q, J = 7.1 Hz, 2H), 4.02 (s, 
4H), 3.41 (m, 2H), 3.07 (t, J = 5.5 Hz, 2H), 2.77 (t, J = 7.6 Hz, 2H), 1.24 (t, J = 7.1 Hz, 
3H) ppm. 13C NMR (CDCl3, 100 MHz) δ 171.6, 164.7, 163.9, 158.8, 150.6, 149.3, 136.7, 
134.9, 131.1, 130.1, 127.8, 124.3, 123.3, 122.7, 122.3, 120.8, 108.9, 104, 60.5, 59.7, 51, 
41, 35.8, 32.9, 29.7, 14.2 ppm. HR-MS(ESI+): m/z calculated for C31H32N5O4 [M+H]+ 
538.2454; found 538.2449. 
 
3-(6-((2-(Bis(pyridin-2-ylmethyl)amino)ethyl)amino)-1,3-dioxo-1H-
benzo[de]isoquinolin-2(3H)-yl)propanoic acid (DPA-Naph-OH) (5) 
To a solution of 4 (0.60 g, 1.12 mmol) in methanol (10 mL) was added NaOH (0.14 g, 3.40 
mmol) in H2O (10 mL). The solution was heated to reflux overnight. Upon cooling to RT, 
the solvent was removed under reduced pressure, and water (30 mL) was added. The pH 
of the solution was adjusted to 7 with 1 M HCl, and the product extracted with DCM. The 
organic layer was washed with water and brine, dried over MgSO4, filtered and evaporated 
to give the product as a yellow-orange solid. Yield: 0.48 g, 0.94 mmol, 84%. 1H NMR 
(CDCl3, 400 MHz) δ 8.65 (d, J = 8.3 Hz, 1H), 8.59 – 8.56 (m, 2H), 8.53 (d, J = 7.3 Hz, 
1H), 8.34 (d, J = 8.4 Hz, 1H), 7.65 – 7.53 (m, 4H), 7.37 (d, J = 7.8 Hz, 2H), 7.19 – 7.13 
(m, 2H), 6.47 (d, J = 8.6 Hz, 1H), 4.47 (t, J = 7.2 Hz, 2H), 4.01 (s, 4H), 3.39 (s, 2H), 3.03 
(dd, J = 5.6, 5.2 Hz, 2H), 2.78 (dd, J = 7.1 Hz, 2H). 13C NMR (CDCl3, 100 MHz) δ 164.8, 
164.1, 158.41, 150.6, 149.0, 136.9, 135.0, 131.2, 130.0, 127.8, 124.3, 123.6, 122.5, 122.4, 
120.6, 108.6, 104.0, 77.3, 77.0, 76.7, 59.6, 51.2, 40.9, 35.8. HR-MS (ESI+): m/z calculated 
for C29H28N5O4 [M+H]+ 510.2144; found 510.2141. 
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General Peptide Synthesis 
Peptides were synthesized by standard Fmoc solid-phase peptide chemistry on Rink Amide 
MBHA resin (0.1 mmol scale, 0.52 mmol/g resin loading) in an automated peptide 
synthesizer (Syrowave, Biotage Inc.) with deprotection and coupling steps carried out at 
room temperature in DMF using HCTU as a coupling agent and N,N-
diisopropylethylamine (DIPEA) as a base. The N-terminus was left Fmoc-protected for 
subsequent modification of the peptides. Alloc deprotection was achieved by treating the 
resin with Pd(PPh3)4 (0.1 equiv.) in the presence of PhSiH3 (20 equiv.) in dry DCM for 45 
minutes. Disulfide bridges were formed by reaction with I2 (10 equiv.) in 4:1 DMF/H2O 
for 1 hour, followed by washing of the resin with DMF (3 x 4 mL), 2% ascorbic acid in 
DMF (3 x 4 mL), then again with DMF (3 x 4 mL). The final Fmoc deprotection was 
achieved by treatment of the resin with 20% piperidine in DMF for 5 and 15 minutes. Upon 
completion of synthesis, the resin was rinsed with DCM and allowed to dry. Peptides were 
cleaved from the resin using 4 mL of 95% trifluoroacetic acid, 2.5% triisopropylsilane, and 
2.5% distilled water for 5 h. The cleavage cocktail was collected into a 50-mL falcon tube 
where 20 mL of ice cold tert-butylmethylether (TBME) was slowly added to precipitate 
the crude peptide. Falcon tubes were centrifuged at 3000 rpm for 10 minutes resulting in a 
peptide pellet. The remaining TBME was decanted and peptide pellet was re-suspended in 
20 mL of fresh ice-cold TBME before being centrifuged again. The resulting peptide pellet 
was dissolved in water, frozen in dry ice and freeze-dried overnight using a lyophilizer. 
The crude peptides were analyzed by analytical HPLC-MS. 
 
Synthesis of T140 (6) 
The D-Lys side chain was protected with a Boc group. The peptide was cleaved from the 
resin following disulfide bridge formation and Fmoc deprotection. Purification was 
performed by preparative HPLC-MS (linear gradient 10-70% Solvent A in B) and was 
obtained as a fluffy white powder with a purity of 95% after freeze drying of the collected 
fractions. HPLC (10-70% Solvent A in B) tR = 9.32 min. HRMS (ESI+): m/z calculated for 
C90H143N34O17S2 [M+H]+ 2036.0807; found 2036.0819. 
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Synthesis of DPA-Naph-T140 (7) 
The D-Lys side chain was protected with an Alloc group. Following Alloc deprotection, 
DPA-Naph-OH (3 equiv.) was coupled to the peptide by activation with HCTU (3 equiv.) 
in the presence of DIPEA (6 equiv.) in DMF for 2 hours. This was followed by disulfide 
bridge formation, Fmoc deprotection and cleavage of the peptide from the resin. 
Purification was performed by preparative HPLC-MS (linear gradient 20-80% Solvent A 
in B) and was obtained as a fluffy bright-yellow powder with a purity of 96% (by HPLC) 
after freeze drying of the collected fractions. HPLC (20-80% Solvent A in B) tR = 8.03 
min. HRMS (ESI+): m/z calculated for C119H168N39O20S2 [M+H]+ 2527.2764; found 
2527.2671. 
 
Synthesis of Re(CO)3-DPA-Naph-T140 (Re-7) 
To a solution of 7 in dH2O (3 mL) in a 5 mL microwave vial was added a 0.1 M solution 
of [Re(CO)3(H2O)3]OTf (1.2 equiv.) in H2O. The reaction was heated to 110 °C for 15 
minutes under microwave irradiation. The peptide was then purified by preparative HPLC-
MS (linear gradient 20-80% Solvent A in B) and was obtained as a fluffy, bright-yellow 
powder with a purity of >98% (by HPLC) after freeze drying of the collected fractions. 
HPLC (20-80% Solvent A in B) tR = 9.63 min. HR-MS(ESI+): m/z calculated for 
C122H167N39O23185ReS2 [M]+ 2795.2063; found 2795.2077. 
 
99mTc-Labelling of 7 
Sodium boranocarbonate (10.0 mg, 0.10 mmol), sodium carbonate (15.0 mg, 0.14 mmol), 
sodium borate (20 mg, 0.05 mmol), and sodium potassium tartrate (22 mg, 0.08 mmol) 
were dissolved in dH2O (1 mL). This solution was transferred to a sterile vial containing 
500-1000 MBq [99mTc]NaTcO4 from a 99Mo/99mTc generator, and then transferred to a 2 
mL microwave vial, which was heated in a microwave reactor for 3.5 minutes at 110 °C to 
form [99mTc]Tc(CO)3(H2O)3+. The mixture was neutralized by the addition of 1 M HCl (0.2 
mL). Approximately 200-500 MBq of [99mTc]Tc(CO)3(H2O)3+ was added to 7 (0.1 mg) in 
dH2O (0.1 mL) in a 2 mL microwave vial and heated to 100 °C for 12 minutes in the 
microwave reactor. Upon cooling, the reaction mixture was purified by semipreparative 
HPLC (linear gradient 20-70% Solvent A in B) to give the labelled peptide in decay 
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corrected radiochemical yields ranging from 60-85%, radiochemical purities >95% and 
molar activities of 36-44 GBq/µmol. 
 
Cell Culture 
U87.CD4 and U87.CD4.CXCR4 cells were obtained through the NIH AIDS Reagent 
Program, Division of AIDS, NIAID, NIH from Dr. Hong Kui Deng and Dr. Dan R. 
Littman.37 PC-3 and DU 145 cells were purchased from ATCC. BPH-1 cells were a 
generous gift from Dr. John Lewis (University of Alberta). U87.CD4.CXCR4 cells were 
maintained in DMEM – high glucose (Sigma) containing 15% fetal bovine serum (FBS), 
1 µg/mL puromycin, 300 µg/mL G418, and 1X penicillin-streptomycin. U87.CD4 cells 
were maintained in DMEM – high glucose (Sigma) containing 10% FBS, 300 µg/mL 
G418, and 1X penicillin-streptomycin. PC-3 cells were maintained in F-12K medium 
(Wisent) supplemented with 10% FBS and 1X penicillin-streptomycin. DU 145 cells were 
maintained in EMEM (Sigma) supplemented with 10% FBS, 1X MEM non-essential 
amino acids (Sigma), 2 mM L-glutamine, 1 mM sodium pyruvate and 1X penicillin-
streptomycin.  BPH-1 cells were maintained in RPMI 1640 medium (Wisent) containing 
10% FBS and 1X penicillin-streptomycin. All cell lines were cultured at 37°C in 
humidified atmosphere with 5% CO2 and passaged 2 to 3 times per week. 
 
Confocal Microscopy 
48 hours prior to the experiment, cells were seeded onto coverslips in 12-well plates 
(100,000 cells/well). The culture media was removed, and each well was then washed with 
phosphate buffered saline (PBS, 1 mL). Re-7 was dissolved in culture media at a 
concentration of 1 µM, and 1 mL of this solution was added to each well. The cells were 
incubated at 37 °C for 1 hour. After the incubation, each well was washed with PBS (2 x 1 
mL) and fixed by the addition of 4% paraformaldehyde in PBS for 15 minutes. Each well 
was then washed with PBS (2 x 1 mL), and the cover slips mounted on slides with 
ProLong® Diamond antifade mountant (Molecular Probes). After allowing the slides to 
cure for 24 hours, cells were imaged by confocal microscopy on an Olympus Fluoview 
FV1000 confocal microscope using a 40x objective. The excitation wavelength was set at 
458 nm and emission collected from 500-550 nm. 
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Competitive Binding Assays 
CXCR4 affinities were determined through competitive binding assays using 
U87.CD4.CXCR4 cells with [125I]-SDF-1 as the radioligand. T140 was used as a reference 
to ensure the validity of the results. The peptide of interest (at concentrations ranging from 
10-12 to 10-6 M) and [125I]-SDF-1 (20 pM) were mixed with the binding buffer (20 mM 
HEPES, 0.5% BSA in PBS, pH 7) in 1.5 mL Eppendorf Protein LoBind vials. A suspension 
of U87.CD4.CXCR4 cells (50,000 cells) was added to each vial to give a final volume of 
300 µL. The vials were shaken at 550 rpm for 20 minutes at 37 °C. Immediately after the 
incubation, the vials were centrifuged at 13000 rpm for 5 minutes and the supernatant 
removed. The cell pellet was washed with 500 µL of 50 mM Tris buffer (pH 7) and 
centrifuged again. The amount of [125I]-SDF-1 bound to the cells was measured using a 
gamma counter (Perkin Elmer). IC50 values were determined by non-linear regression 
analysis to fit a 4-parameter dose response curve using GraphPad Prism (Version 6.0c). 
 
Cellular Uptake Assay 
48 hours prior to the experiment, U87.CD4.CXCR4 and U87.CD4 cells were seeded in 6-
well plates at a density of 3 x 105 cells per well. On the day of the experiment, the cell 
media was aspirated, each well rinsed with Hank’s Balanced Salt Solution (HBSS, 2 x 1 
mL)), and an additional 2 mL of HBSS added to each well. 0.5 MBq of [99mTc]Tc-7 in 100 
µL of HBSS was added to each well and the cells were incubated at 37 °C for 1 hour. The 
supernatant was removed, and each well rinsed with HBSS (1 mL). The combined 
supernatant and washes represented the free radioligand. The cells were then scraped in 
PBS (1 mL) and transferred to tubes for counting. The wells were then rinsed with PBS (2 
x 1 mL) and combined with the cells. The bound and unbound radioactivity was counted 
on a Perkin-Elmer Wizard 1470 gamma counter. Cell uptake was expressed as percentage 
of cell bound activity over total activity. 
 
Biodistribution Studies 
The Western University Animal Use Subcommittee of the Canadian Council on Animal 
Care approved the protocols for all mouse handling and treatment procedures described in 
this study (protocol 2012-033). Male NOD/SCID mice aged 4-6 weeks were 
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subcutaneously injected with U87.CD4.CXCR4 cells (2.5 x 106 cells). After 4-6 weeks, 
when the tumors had grown to a size of ~0.8 cm, 1.5-2.5 MBq of [99mTc]Tc-7 was 
intravenously administered into the tail vein of isoflurane-anesthetized animals (n = 3). The 
animals were sacrificed at two hours post-injection. The tissues and organs of interest were 
removed and weighed before being counted for radioactivity in a gamma counter. 
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Chapter 3 
3 A Study of 99mTc/Re-Tricarbonyl Complexes of 4-Amino-
1,8-Naphthalimides 
3.1 Introduction 
Functionalized 1,8-naphthalimides are an incredibly useful class of molecules that have 
applications as anticancer drugs1,2 and as fluorescent cellular imaging agents.3,4 
Substitution of the naphthyl ring with electron donating substituents creates a 
naphthalimide with an excited state resulting from intramolecular charge transfer (ICT). 
The resulting fluorophore possesses visible light excitation, solvatochromic properties, and 
large Stokes shifts.4 Photophysical properties such as absorption and emission 
wavelengths, quantum yields, and fluorescent lifetimes can be modulated by appending 
metal complexes to the naphthalimide. Metals such as Gd(III),5 Zn(II),6,7 Au(I),8 and 
Re(I)9,10 have been used to this end, and have shown exceptional utility in various cellular 
imaging applications. Rhenium complexes are of particular interest, as a fluorescent ligand 
that can bind rhenium may also bind technetium-99m for the purpose of single photon 
emission computed tomography (SPECT) imaging. Fluorescent rhenium complexes may 
aid in the preclinical development of SPECT imaging agents by providing insight into 
cellular localization and tissue uptake, as well as having uses in staining of ex vivo tissue 
samples.11–14 
The fac-Re/99mTc(I)-tricarbonyl core is a convenient and robust system that allows for the 
use of a wide variety of tridentate ligands to coordinate the metal, resulting in kinetically 
stable complexes.15 The choice of ligand is critical for determining the overall charge of 
the metal complex, which can have an impact on hydrophilicity, cellular uptake and 
localization, as well as biodistribution in an in vivo setting. Pope et al. have recently 
developed a set of 4-amino-1,8-naphthalimide ligands containing a di-(2-picolyl)amine 
binding unit to coordinate Re(I)-tricarbonyl and varying napthlalimide substituents.9 This 
chelation system imparts an overall positive charge to the Re(I) complex. Coordination of 
the ligand to Re(I) caused a hypsochromic shift of the absorption and fluorescence 
wavelengths, as well as an increase in the fluorescence quantum yields due to suppression 
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of quenching by photo-induced electron transfer (PeT). The complexes also showed 
increased cellular uptake over the free ligand in most cases. The effect of changing the 
naphthalimide substituent showed tunability of cellular uptake of these naphthalimides. For 
the purpose of targeted imaging agents, we wished to observe instead the impact that the 
charge of the metal complex has on the photophysical and cellular uptake characteristics. 
This information could be used for the development and optimization of bioconjugates 
containing Re/99mTc naphthalimide complexes for fluorescence and SPECT imaging. 
In this work, we report the synthesis of three naphthalimide ligands that have been 
appended with different chelation systems. First, L1 contains a di-(2-picolyl)amine ligand 
and is comparable to those developed by Pope et al. to serve as a reference. Two novel 
ligands were synthesized: L2, containing a binding unit with one picolyl and one carboxyl 
arm which results in a neutral metal complex, and L3, with an iminodiacetate ligand 
resulting in a negatively charged metal complex (Figure 3.1). We have compared the 
photophysical properties of the ligands and their Re(I) complexes and evaluated the cellular 
uptake of the Re(I) complexes by confocal microscopy. Finally, we demonstrate for the 
first time, the radiolabelling of the three ligands with technetium-99m to highlight their 
utility as components of SPECT imaging agents. 
 
Figure 3.24:  Structures of the three naphthalimide ligands coordinated to Re or 99mTc. 
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3.2 Results and Discussion 
3.2.1 Synthesis and Structural Evaluation 
The three naphthalimide ligands (L1-L3) were chosen to afford Re(I) complexes with three 
different charge states; positive (Re-L1), neutral (Re-L2) and negative (Re-L3). All three 
ligands were derived from the precursor amine 3, which was synthesized in three steps 
from commercially available 4-chloro-1,8-naphthalic anhydride (Scheme 3.1). The chloro-
substituted naphthalimide 1 was formed in 84% yield by reaction of the anhydride with 
glycine methyl ester hydrochloride in ethanol. The Boc protected amine 2 was made in 
quantitative yield by reaction of 1 with tert-butyl (2-aminoethyl)carbamate in DMSO. This 
was followed by deprotection of the Boc group with TFA to afford the amine 3 in 41% 
yield. L1 was then formed by reaction of 3 with 2-picolylchloride in DMF in 68% yield. 
L2 was synthesized in 37% yield via a one-pot asymmetric reductive alkylation of 3 with 
2-pyridinecarboxaldehyde and glyoxylic acid monohydrate using sodium 
cyanoborohydride. Similarly, L3 was synthesized by reductive alkylation of 3 with 
glyoxylic acid monohydrate using sodium cyanoborohydride in 50% yield.  
The ligands were fully characterized by NMR and mass spectrometry. The Re(I)-
tricarbonyl complexes were then formed by reaction of the ligands with fac-
[Re(CO)3(CH3CN)3]OTf in chloroform at 60 °C. As with the free ligands, the complexes 
were characterized by NMR and mass spectrometry. In the 1H NMR spectra of Re-L1, the 
ethylene protons from the linker and the methylene protons of the picolyl arms were 
deshielded in comparison to that of L1 (Figure 3.2, left). A characteristic pair of signals 
were observed due to the diastereotopic splitting of the methylene protons of the picolyl 
arms. The coupling constant was 16.4 Hz, corresponding to a geminal coupling. This data 
confirms that the di-(2-picolyl)amine is indeed bound to the rhenium atom as previously 
reported by Pope et al. 
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Scheme 3.2:  Synthetic route to the three naphthalimide ligands and their Re(I)-tricarbonyl 
complexes. 
The 13C NMR of Re-L1 showed two new resonances in comparison to L1 at 197.0 and 
196.1 ppm which are characteristic of the equatorial and axial carbonyl ligands 
respectively. In the 1H NMR spectrum of Re-L3, the ethylene protons from the linker were 
deshielded as with Re-L1, but to a much lesser extent. The diastereotopic methylene 
protons on the carboxyl arms also show a geminal coupling of 15.8 Hz. However, one pair 
of the protons is slightly deshielded, while the other is slightly shielded in comparison to 
L3 (Figure 3.2, right). For Re-L2 the picolyl methylene protons shifted similarly to that of 
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Re-L1 and the carboxyl methylene protons shifted similarly to those of Re-L3. Therefore, 
the methylene proton shift is characteristic of the chelating arm and not of the overall 
complex charge. Both pairs of methylene protons showed geminal couplings, again 
confirming the binding mode. 
 
Figure 3.25: 1H NMR spectroscopy chemical shifts of the chelator arm methylene (red) 
and linker ethylene (black) protons of L1 (top left) and L3 (top right) and changes upon 
rhenium coordination (bottom). 
3.2.2 Photophysical Properties 
The UV/Vis absorption and fluorescence properties of the ligands were compared to those 
of the rhenium complexes (Table 3.1). L1 had a broad absorption band with a maximum 
at 439 nm. This band is assigned to an intramolecular charge transfer (ICT) of an N®p* 
character. L2 and L3 had a similar broad band, however the maximum for both ligands 
was at 436 nm, slightly higher in energy in comparison to L1. Interestingly, the molar 
extinction coefficient of L1 was significantly higher than those of L2 and L3. It is known 
that the nature of the amino substituent on the naphthalimide ring can impact the 
absorbance and energy of the ICT band due to orientation effects.10,16 The absorption band 
for Re-L1 experienced a hypsochromic shift and a reduction in the molar extinction 
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coefficient in comparison to L1, similar to the analogues previously reported by Pope et 
al. The ICT absorption band for Re-L2 and Re-L3 underwent similar hypsochromic shifts, 
but an increase in the molar absorption coefficients was observed. 
Fluorescence emission maxima varied between the three ligands (Table 3.1). L1 had the 
lowest energy emission at 528 nm, while L3 had the highest energy emission at 516 nm. 
Rhenium coordination caused a hypsochromic shift of the emission maximum for all three 
ligands, however the extent of the shift depended on the charge of the complex. The 
positively charged Re-L1 induced the largest shift from 528 nm to 506 nm, while the 
negatively charged Re-L3 induced the smallest shift from 516 to 512 nm. The excitation 
and emission wavelengths for all three complexes are highly compatible with confocal 
fluorescence microscopy. The UV/Vis and fluorescence spectra are shown in Figure 3.3.  
The quantum yield of L1 increased upon rhenium coordination due to suppression of PeT 
quenching pathways as previously reported for this type of complex. However, metal 
coordination had little effect on the quantum yields of L2 and L3. This suggests that either 
quenching pathways are not suppressed in Re-L2 and Re-L3, or the quenching pathways 
were not present in L2 and L3. The quantum yields for both Re-L2 and Re-L3 were lower 
than that of Re-L1, however they are still sufficiently high for use in confocal fluorescence 
microscopy. 
 
Figure 3.26: UV/Vis absorption (A-C) and fluorescence excitation/emission spectra (D-
F) of the ligands (lEx = 440 nm) and their rhenium complexes (lEx = 425 nm) in CH3CN 
(20 µM). 
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Table 3.2: Photophysical properties of the naphthalimide ligands and their Re(I)-
tricarbonyl complexes. 
Compound lAbs (nm)a e (L×mol-1cm-1)a lEx (nm)a lEm (nm)a ffb 
L1 439 14500 444 528 0.27 
L2 436 9950 438 520 0.24 
L3 436 8300 438 516 0.13 
Re-L1 424 14100 422 506 0.45 
Re-L2 425 14750 424 510 0.23 
Re-L3 428 15000 424 512 0.13 
aIn CH3CN (20 µM). b In aerated CH3CN relative to [Ru(bpy)3](PF6)2 in aerated CH3CN (ff = 
0.018). 
3.2.3 Confocal Microscopy 
The cellular permeability of the three Re(I) complexes was evaluated in OVCAR-8 ovarian 
cancer cells by confocal fluorescence microscopy (Figure 3.4, see Appendix B for DIC 
images). The cells were incubated with the complexes at a concentration of 20 µM and 
were then fixed and mounted on slides for imaging. The ethyl ester variant of Re-L1 
previously reported by Pope et al was shown to have good cellular permeability in human 
osteoarthritic cells, with cytoplasmic and mitochondrial staining. Re-L1 showed similar 
uptake and distribution in the OVCAR-8 cells, with strong signal emanating from the 
cytoplasm, and organelles (Figure 3.4, D). Re-L2 showed decreased permeability in 
comparison to Re-L1 (Figure 3.4, B). Less cytoplasmic uptake was observed, though there 
was still a granular staining pattern, likely due to uptake in mitochondria (Figure 3.4, E). 
The positive charge of Re-L1 along with the increased lipophilicity of the picolyl ligands 
likely are responsible for the high permeability across the negatively charged phospholipid 
membrane in comparison to the neutral complex Re-L2. Due to the negative charge on Re-
L3, it showed poor cellular permeability (Figure 3.4, C). A weak fluorescent signal was, 
however, observed emanating from some structures within the cells (Figure 3.4, F). It has 
previously been reported that hydrophobic imaging labels may increase non-specific 
uptake in an in vivo setting.17 Therefore, the higher polarity of Re-L2 and Re-L3 suggests 
that the technetium-99m labelled variants may be ideal for conjugation to biomolecules for 
the purpose of SPECT imaging in order to reduce off-target accumulation of an imaging 
agent. 
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Figure 3.27: Confocal fluorescence microscope images of OVCAR-8 cells (A-C 40x, D-
F 100x) incubated with: (A, D) Re-L1; (B, E) Re-L2; and (C, F) Re-L3 at a concentration 
of 20 µM (lEx = 458 nm). 
While the cellular uptake of Re-L1 was the highest, the high cytoplasmic localization could 
obscure fluorescent signals from other cellular structures. For applications where specific 
targeting of cellular structures is required, Re-L2 might be a more suitable imaging agent. 
In any case, we have demonstrated that changing the polarity and charge of the rhenium 
complex drastically alters the cellular permeability and localization. This provides the 
opportunity to create bioconjugates of these complexes with the potential to tune the 
pharmacokinetic properties, cellular permeability and biodistribution depending on the 
charge of the chosen complex.   
3.2.4 Radiolabelling with Technetium-99m 
The previously reported di-(2-picolyl)amine substituted 4-amino-1,8-naphthalimides had 
not been labelled with technetium-99m, only with the non-radioactive analogue rhenium 
to exploit the fluorescence properties for fluorescence microscopy applications. To 
demonstrate the applicability of these ligands as components of SPECT imaging agents, 
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we radiolabelled them with technetium-99m. Under aqueous conditions, the ligands were 
reacted with [99mTc][Tc(CO)3(H2O)3]+ to form the fac-99mTc(I)-tricarbonyl complexes.  
Initially, we chose a temperature of 100 °C for 15 minutes under microwave irradiation to 
radiolabel L1. A single radiolabelled product was observed by analytical HPLC of the 
reaction mixture; however, the retention time was significantly shorter than for that of the 
rhenium complex. We surmised that the methyl ester was hydrolyzed in the aqueous 
environment under the high temperatures. Reduction of the temperature to 70 °C for 15 
minutes prevented hydrolysis from occurring, and a single radiolabelled product was 
observed that matched the retention time of the corresponding rhenium complex (Figure 
3.5). These same conditions were applied to L2 and L3. The labelled products were isolated 
by semi-preparative HPLC to remove any unlabelled ligand, resulting in radiochemical 
yields of the three complexes ranging from 60-95% and radiochemical purities of greater 
than 95%. The ease of labelling and purification of the ligands under mild aqueous 
conditions makes them suitable as components of SPECT imaging agents. 
 
Figure 3.28: HPLC chromatograms (System II, 20-80% Solvent A) of the 99mTc-labelled 
ligands (blue) and their Re-coordinated standards (pink). 
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3.3 Conclusions 
In summary, we have reported the synthesis and photophysical properties of two new 
naphthalimide ligands and their Re(I)-tricarbonyl complexes, and compared them to an 
analogue of a previously reported complex. The photophysical properties of the three 
complexes are ideal for confocal fluorescence microscopy. Altering the charge and polarity 
of the metal complex drastically altered the cellular permeability of the ligands. Re-L1 
showed the highest cellular permeability. The neutral complex, Re-L2, although having 
decreased cellular permeability compared to Re-L1, had similar cellular distribution, 
except with lower cytoplasmic uptake. The cellular uptake of the negatively charged 
complex, Re-L3, was limited due to its high polarity, but this property may be ideal for 
technetium-99m labelled SPECT imaging agents to reduce non-specific binding in vivo. 
The differing cellular permeability of the three complexes demonstrates their vastly 
different polarity, which may be exploited for use in in vivo imaging studies. We have also 
demonstrated the 99mTc-labelling of the three ligands in high yields and radiochemical 
purities, making them suitable as components of SPECT imaging agents. Bioconjugates of 
these naphthalimides may have applications as dual modality imaging agents for in vitro 
and ex vivo tissue staining by fluorescence, and as in vivo SPECT imaging agents. 
3.4 Experimental 
3.4.1 General Experimental 
All reagents were purchased from commercial sources and used without further 
purification. NMR spectra were recorded on a Bruker AvIII HD 400 spectrometer. All 
chemical shifts are reported in ppm and referenced to the residual solvent peaks. High 
resolution mass spectra were recorded on a Thermo Scientific Double Focusing Sector 
mass spectrometer for EI or a Bruker micrOTOF II for ESI in either positive or negative 
mode. Analytical reversed-phase HPLC-MS was performed on a system consisting of an 
Agilent Zorbax SB-C18 column (5 µm, 4.6 x 150 mm), Waters 600 controller and binary 
solvent pump and a Waters Quattro Micro API mass spectrometer (System I). Mass spectra 
were collected using an ESI source in positive ion mode. The linear gradient solvent system 
comprised of solvent A (CH3CN + 0.1 % TFA) and solvent B (H2O + 0.1 % TFA) at a flow 
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rate of 1.5 mL/min over 10 minutes with a 5-minute wash cycle at 95% solvent A. The 
UV/Vis absorbance was detected using a Waters 2998 photodiode array detector. 
Preparative reversed-phase HPLC-MS was performed on the same system using an Agilent 
Zorbax PrepHT SB-C18 column (5 µm, 21.2 x 150 mm) at a flow rate of 20 mL/min. After 
purification, the collected fractions were frozen at -78 °C, and lyophilized. Analytical 
radio-HPLC was performed on a system comprising of an Agilent Zorbax SB-C18 column 
(5 µm, 4.6 x 150 mm), Waters 600 controller and Binary Solvent Pump, a Carroll & 
Ramsey radiometric detector connected to a Waters e-Sat/IN module and Waters 2498 dual 
absorbance UV/Vis detector (System II). The linear gradient solvent system comprised of 
solvent A (CH3CN + 0.1 % TFA) and solvent B (H2O + 0.1 % TFA) at a flow rate of 1.5 
mL/min over 10 minutes with a 5-minute wash cycle at 95% solvent A. Semi-preparative 
radio-HPLC was performed on the same system with an Agilent Zorbax SB-C18 column 
(3.5 µm, 4.6 mm x 150 mm) at a flow rate of 4 mL/min. UV-Vis spectra were recorded on 
an Agilent Cary 60 UV-Vis spectrophotometer. Fluorescence spectra were recorded on a 
Photon Technologies International, Inc. Quanta Master – 7/2005. Quantum yields were 
determined on aerated acetonitrile solutions using [Ru(bpy)3](PF6)2 in acetonitrile (ff = 
0.018) as a reference.18 fac-[Re(CO)3(CH3CN)3]OTf was prepared according to the 
literature.19 
 
Methyl 2-(6-chloro-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)acetate (1) 
4-Chloro-1,8-napthalic anhydride (2.00 g, 8.6 mmol), triethylamine (0.85 g, 8.5 mmol) and 
glycine methyl ester hydrochloride (1.53 g, 17.2 mmol) were added to ethanol (50 mL) and 
heated to reflux for 16 hours. The orange solution was cooled to room temperature, 
resulting in the formation of the product as an off-white precipitate that was collected by 
filtration, washed with ice cold ethanol and then dried under vacuum (2.2 g, 84%). 1H NMR 
(400 MHz; CDCl3) δ 8.64 (dd, J = 7.3, 1.0 Hz, 1H), 8.58 (dd, J = 8.5, 1 Hz, 1H), 8.48 (d, 
J = 7.3 Hz, 1H), 7.89 – 7.76 (m, 2H), 4.94 (s, 2H), 3.78 (s, 3H). 13C NMR (CDCl3; 100 
MHz) δ 168.5, 163.5, 163.2, 139.7, 132.5, 131.6, 131.2, 129.5, 129.3, 128.0, 127.5, 122.7, 
121.2, 52.7, 41.4. HRMS (EI): m/z calculated for C15H10ClNO4 [M]+ 303.0298; found 
303.0284.  
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Methyl 2-(6-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-1,3-dioxo-1H-
benzo[de]isoquinolin-2(3H)-yl)acetate (2) 
tert-Butyl (2-aminoethyl)carbamate (3.5 g, 21.7 mmol) and compound 1 (2.2 g, 7.2 mmol) 
were dissolved in DMSO (10 mL) and heated to 70 °C for 16 hours. The resulting deep red 
solution was cooled to room temperature and the pH neutralized with 0.1 M HCl. The 
solution was diluted with dichloromethane and washed with water. After drying with 
MgSO4 the dichloromethane layer was reduced to a minimal volume under vacuum. 
Hexanes was added, resulting in the precipitation of the product as an orange solid which 
was collected by filtration, washed with cold hexanes, and dried under vacuum (3.07 g, 
quant.). 1H NMR (400 MHz; CDCl3) δ 8.45 (d, J = 7.3 Hz, 1H), 8.36 (d, J = 8.4 Hz, 1H), 
8.24 (d, J = 8.4 Hz, 1H), 7.49 (t, J = 7.3 Hz, 1H), 7.04 (br. s, 1H), 6.51 (d, J = 8.5 Hz, 1H), 
4.95 (s, 2H), 3.79 (s, 3H), 3.61 (q, J = 5.6 Hz, 2H), 3.43 (q, J = 4.4 Hz, 2H), 1.48 (s, 9H). 
13C NMR (100 MHz; CDCl3) δ 169.7, 164.6, 163.8, 158.4, 150.8, 135.1, 131.5, 127.7, 
124.7, 120.5, 109.1, 103.6, 80.7, 52.6, 46.4, 41.2, 39.6, 29.8, 28.5. HRMS (ESI+): m/z 
calculated for NaC22H25N3O6 [M+Na]+  450.1641; found 450.1644. 
Methyl 2-(6-((2-aminoethyl)amino)-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-
yl)acetate (3) 
Compound 2 (3.0 g, 7.02 mmol) was dissolved in dichloromethane (10 mL) and 
trifluoroacetic acid (10 mL) and the solution was stirred for 24 hours at room temperature. 
The solvent was removed under vacuum and the resulting TFA salt was dissolved in water 
and the pH was neutralized with saturated sodium bicarbonate. The product was extracted 
into DCM, the organic layer was collected and dried with Na2SO4. The solvent was then 
removed under reduced pressure producing a yellow solid (0.95 g, 41%). 1H NMR (400 
MHz; CD3OD) δ 8.50 – 8.38 (m, 2H), 8.29 (d, J = 8.5 Hz, 1H), 7.61 (dd, J = 8.3, 7.5 Hz, 
1H), 6.80 (d, J = 8.5 Hz, 1H), 4.86 (s, 2H), 3.78 (s, 3H), 3.75 (t, J = 6.2 Hz, 2H), 3.34 (t, J 
= 6.2 Hz, 2H). 13C NMR (100 MHz; CD3OD) δ 170.9, 165.6, 165.1, 151.9, 135.8, 132.5, 
131.1, 129.6, 126.0, 123.0, 122.2, 110.4, 105.3, 52.9, 42.0, 41.7, 39.2. HRMS (ESI+): m/z 
calculated for C17H18N3O4 [M+H]+ 328.1297; found 328.1284. 			
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L1 
To a solution of compound 3 (50 mg, 0.15 mmol) in DMF (4 mL) was added K2CO3 (84 
mg, 0.61 mmol), KI (51 mg, 0.31 mmol) and 2-picolylchloride hydrochloride (50 mg, 0.31 
mmol). The orange solution was heated to 50 °C for 48 hours. The solution was partitioned 
into water (30 mL) and chloroform (50 mL). The aqueous layer was extracted 3 times with 
chloroform, and the combined organics were dried over Na2SO4 and concentrated under 
reduced pressure to give the product as a yellow-orange solid (L1) (53 mg, 68%). UV/Vis 
(CH3CN): lmax/nm (e /L×mol-1cm-1) = 439 (14 500) 340 (2750) 324 (3450) 282 (19 000) 
269 (29 500) 263 (33 000) 256 (32 000). 1H NMR (400 MHz; CDCl3) δ 8.85 (dd, J = 8.4, 
1.0 Hz, 1H), 8.63 (dd, J = 7.4, 1.0 Hz, 1H), 8.59 – 8.56 (m, 2H), 8.42 (d, J = 8.5 Hz, 1H), 
7.98 (s, 1H), 7.69 (dd, J = 8.4, 7.4 Hz, 1H), 7.56 (td, J = 7.8, 1.8 Hz, 2H), 7.37 (d, J = 7.8 
Hz, 2H), 7.15 (ddd, J = 7.5, 4.9, 1.0 Hz, 2H), 6.55 (d, J = 8.5 Hz, 1H), 4.96 (s, 2H), 4.01 
(s, 4H), 3.77 (s, 3H), 3.43 – 3.36 (m, 2H), 3.09 – 3.02 (m, 2H). 13C NMR (100 MHz; 
CDCl3) δ 169.3, 164.8, 163.8, 158.9, 151.0, 149.4, 136.8, 135.4, 131.6, 130.5, 128.2, 124.4, 
123.4, 122.5, 121.0, 108.6, 104.2, 59.9, 52.5, 51.1, 41.3, 41.1. HRMS (ESI+): m/z 
calculated for C29H28N5O4 [M+H]+ 510.2142; found 510.2139. 
 
fac-[Re(CO)3(L1)]OTf (Re-L1) 
L1 (53 mg, 104 µmol) and fac-[Re(CO)3(CH3CN)3]OTf (56 mg, 104 µmol) were added to 
chloroform (5 mL) and heated to 60 °C  for 18 hours. The solution was cooled to room 
temperature and diethyl ether was added to induce precipitation of the product as a yellow 
solid, which was collected by filtration, washed with diethyl ether and dried under vacuum 
giving Re-L1 (72 mg, 74%). UV/Vis (CH3CN): lmax/nm (e /L×mol-1cm-1) = 424 (14 100) 
338 (4150) 321 (5700) 276 (25 500) 268 (34 800) 259 (35 500) 253 (34 000). 1H NMR 
(400 MHz; acetone-d6) δ 8.99 – 8.96 (m, 2H), 8.67 (d, J = 8.5 Hz, 1H), 8.50 (dd, J = 7.3, 
1.0 Hz, 1H), 8.38 (d, J = 8.5 Hz, 1H), 8.05 (td, J = 7.3, 1.6 Hz, 2H), 7.74 – 7.67 (m, 3H), 
7.48 (t, J = 6.0 Hz, 2H), 7.43 (t, J = 5.3 Hz, 1H), 7.14 (d, J = 8.5 Hz, 1H), 5.54 (d, J = 16.4 
Hz, 2H), 5.28 (d, J = 16.4 Hz, 2H), 4.85 (s, 2H), 4.51 (t, J = 6.6 Hz, 2H), 4.33 – 4.27 (m, 
2H), 3.73 (s, 3H). 13C NMR (100 MHz; acetone-d6) δ 197.0, 196.1, 169.7, 164.6, 163.7, 
161.9, 152.9, 151.0, 141.5, 135.1, 131.9, 130.8, 129.1, 126.7, 125.8, 124.7, 123.2, 121.9, 
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110.4, 105.4, 68.7, 68.6, 52.4, 41.5, 40.6, 40.5. HRMS (ESI+): m/z calculated for 
C32H27N5O7185Re [M]+ 778.1440; found 778.1471.  
 
L2 
Compound 3 (50 mg, 0.15 mmol) sodium acetate (50 mg, 0.61 mmol), acetic acid (70 µL, 
1.22 mmol) and 2-pyridinecarboxaldehyde (16 mg, 0.15 mmol) were dissolved in methanol 
(5 mL) and heated to 65 °C for 16 hours. Upon cooling to room temperature, glyoxylic 
acid monohydrate (21 mg, 0.23 mmol) and NaBH3CN (21 mg, 0.34 mmol) were added, 
and the solution stirred at room temperature for 24 hours. The solvent was removed under 
reduced pressure and the crude product was purified by preparative HPLC (System I, 20-
80%) to give the product as a hygroscopic orange solid (27 mg, 37%). UV/Vis (CH3CN): 
lmax/nm (e /L×mol-1cm-1) = 436 (9950) 339 (1930) 322 (2350) 279 (13 000) 268 (22 700) 
261 (25 500) 255 (24 500). 1H NMR (400 MHz; CD3OD) δ 8.53 – 8.47 (m, 2H), 8.33 – 
8.29 (m, 1H), 8.22 (d, J = 8.5 Hz, 1H), 8.05 (td, J = 7.9, 1.6 Hz, 1H), 7.76 (d, J = 7.9 Hz, 
1H), 7.67 (dd, J = 8.5, 7.4 Hz, 1H), 7.51 – 7.46 (m, 1H), 6.64 (d, J = 8.6 Hz, 1H), 4.88 (s, 
2H), 4.42 (s, 2H), 3.92 (s, 2H), 3.78 (s, 3H), 3.63 (t, J = 6.0 Hz, 2H), 3.34 (t, J = 6.0 Hz, 
2H). 13C NMR (100 MHz; CD3OD) δ 173.7, 170.9, 165.7, 165.1, 155.4, 152.0, 145.0, 
144.4, 135.9, 132.6, 131.3, 129.6, 126.6, 126.0, 125.9, 123.1, 122.0, 109.6, 105.3, 58.2, 
56.5, 54.1, 52.9, 42.0, 41.4. HRMS (ESI+): m/z calculated for C25H25N4O6 [M+H]+ 
477.1774; found 477.1776.  
 
fac-Re(CO)3(L2) (Re-L2) 
Prepared as for Re-L1 but using L2 (22 mg, 46 µmol) and fac-[Re(CO)3(CH3CN)3]OTf 
(25 mg, 46 µmol). Precipitation with diethyl ether gave crude product which was purified 
by preparative HPLC (System I, 35-85%) to give the pure product as a yellow solid (10 
mg, 29%). UV/Vis (CH3CN): lmax/nm (e /L×mol-1cm-1) = 425 (14 750) 340 (3800) 323 
(4950) 277 (23 500) 268 (29 000) 262 (34 500) 255 (34 000). 1H NMR (400 MHz; CD3CN) 
δ 8.80 (d, J = 5.6 Hz, 1H), 8.56 – 8.53 (m, 1H), 8.47 – 8.40 (m, 2H), 8.09 – 8.02 (m, 1H), 
7.77 – 7.70 (m, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.53 – 7.46 (m, 1H), 6.94 (d, J = 8.5 Hz, 
1H), 6.36 (br. s, 1H), 4.83 (d, J = 16 Hz 1H), 4.83 (s, 2H) 4.61 (d, J = 16 Hz, 1H), 4.09 – 
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3.98 (m, 2H), 3.95 – 3.85 (m, 3H), 3.72 (s, 3H), 3.58 (d, J = 16.6 Hz, 1H). HRMS (ESI+): 
m/z calculated for C28H24N4O9185Re [M+H]+ 745.1073; found 745.1082.  
 
L3 
Compound 3 (50 mg, 0.15 mmol), sodium acetate (50 mg, 0.61 mmol), acetic acid (70 µL, 
1.22 mmol) glyoxylic acid monohydrate (42 mg, 0.46 mmol) and NaBH3CN (21 mg, 0.34 
mmol) were dissolved in methanol (5 mL) and stirred at room temperature for 48 hours. 
The solvent was removed under reduced pressure and the crude product purified by 
preparative HPLC (System I, 15-70%) to give the product as a yellow solid (34 mg, 50%). 
UV/Vis (CH3CN):  lmax/nm (e /L×mol-1cm-1) = 436 (8700) 339 (1900) 322 (2300) 279 (11 
300) 269 (20 900) 261 (22 500) 255 (21 500). 1H NMR (400 MHz; CD3OD) δ 8.64 (dd, J 
= 8.4, 1 Hz, 1H), 8.48 (dd, J = 7.4, 1.0 Hz, 1H), 8.33 (d, J = 8.6 Hz, 1H), 7.62 (dd, J = 8.4, 
7.4 Hz, 1H), 6.77 (d, J = 8.6 Hz, 1H), 4.87 (s, 2H), 3.87 (s, 4H), 3.77 (s, 3H), 3.58 (t, J = 
5.8 Hz, 2H), 3.37 (t, J = 5.8 Hz, 2H). 13C NMR (100 MHz; CD3OD) δ 173.3, 170.8, 165.9, 
165.2, 152.5, 136.2, 132.5, 131.4, 130.0, 125.7, 122.9, 122.0, 109.3, 105.3, 55.8, 53.5, 52.9, 
42.0, 41.3. HRMS (ESI-): m/z calculated for C21H20N3O8 [M-H]- 442.1250; found 
442.1262.  
 
fac-Na[Re(CO)3(L3)] (Re-L3) 
L3 (25 mg, 56 µmol) and fac-[Re(CO)3(CH3CN)3]OTf (31 mg, 56 µmol) and sodium 
bicarbonate (10 mg, 113 µmol) were added to chloroform (5 mL) and heated to 60 °C  for 
18 hours then cooled to room temperature. The solvent was removed, and the residue taken 
up in methanol (2 mL) and the residual salts were removed by filtration. The product was 
precipitated by the addition of diethyl ether (10 mL) to give the product as a yellow-orange 
solid that was collected by filtration (16 mg, 39%). UV/Vis (CH3CN): lmax/nm (e /L×mol-
1cm-1) = 428 (15 000) 340 (2500) 324 (3200) 278 (22 500) 269 (31 500) 262 (33 000) 256 
(32 000). 1H NMR (400 MHz; CD3OD) δ 8.53 – 8.44 (m, 2H), 8.37 (d, J = 8.6 Hz, 1H), 
7.64 (dd, J = 8.4, 7.4 Hz, 1H), 6.89 (d, J = 8.6 Hz, 1H), 4.89 (s, 2H), 3.94 (d, J = 15.8 Hz, 
2H), 3.88 – 3.72 (m, 9H). 13C NMR (100 MHz; CD3OD) δ 198.8, 197.6, 182.7, 171.0, 
165.8, 165.1, 152.1, 136.1, 132.5, 131.3, 129.6, 125.9, 123.1, 122.1, 110.0, 105.5, 67.9, 
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64.2, 52.9, 42.0, 40.7. HRMS (ESI-): m/z calculated for C24H19N3O11185Re [M]- 710.0549; 
found 710.0540.  
General procedure for radiolabelling with technetium-99m 
A lyophilized powder containing sodium boranocarbonate (10.0 mg, 0.10 mmol), sodium 
carbonate (15.0 mg, 0.14 mmol), sodium borate (20 mg, 0.05 mmol), and sodium 
potassium tartrate (22 mg, 0.08 mmol) was dissolved in 1 mL of deionized water. This 
solution was transferred to a sterile vial containing 1 GBq of [99mTc]NaTcO4 from a 
99Mo/99mTc generator, and then transferred to a 2 mL microwave vial. The reaction mixture 
was heated in a microwave reactor (Biotage Inc.) for 3.5 minutes at 110 °C to form 
[99mTc][Tc(CO)3(H2O)3]+. The pH of the mixture was neutralized by the addition of 1 M 
HCl (0.2 mL). 150-250 MBq of the [99mTc][Tc(CO)3(H2O)3]+ was transferred to a 2 mL 
microwave vial containing the ligand in methanol (0.1 mL), and the volume made up to 1 
mL with deionized water. The resulting solution was heated in the microwave reactor at 70 
°C for 15 minutes. The radiolabelled products were then directly purified by semi-
preparative HPLC (System II, 20-80%). The identity of the radiolabelled product was 
confirmed by comparison of the retention time with the corresponding rhenium coordinated 
ligand. 
 
[99mTc]fac-[Tc(CO)3(L1)]+ ([99mTc]Tc-L1) 
L1 (0.5 mg) was used for labelling. Radiochemical yields: 74 ± 13%. Radiochemical 
purities: 99 ± 1%. HPLC (System II, 20-80 %) tR = 10.0 min. 
 
[99mTc]fac-Tc(CO)3(L2) ([99mTc]Tc-L2) 
L2 (0.1-0.2 mg) was used for labelling. Radiochemical yields: 66 ± 10%. Radiochemical 
purities: 98 ± 2%. HPLC (System II, 20-80%) tR = 9.3 min. 
 
[99mTc]fac-[Tc(CO)3(L3)]- ([99mTc]Tc-L3) 
L3 (0.5 mg) was used for labelling. Radiochemical yields: 90 ± 5%. Radiochemical 
purities: 96 ± 4%. HPLC (System II, 20-80%) tR = 7.8 min. 
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Cell Culture 
OVCAR-8 cells were cultured in RPMI 1640 culture medium (Wisent) supplemented with 
10% fetal bovine serum (Wisent) and 1X penicillin-streptomycin (Wisent) in a 37 °C 
incubator with a 5% CO2 atmosphere. Cells were passaged 2-3 times per week.  
 
Fluorescence Confocal Microscopy 
OVCAR-8 cells were seeded at a density of 100,000 cells per well in 12-well plates 
containing glass coverslips and allowed to adhere for 24 hours. The culture medium was 
removed, and the wells washed with phosphate buffered saline (PBS). A stock solution of 
each rhenium complex in DMSO (80 µL, 1 mM) was diluted to 4 mL in culture medium 
giving a 20 µM solution. 1 mL of solution was added to each well (n = 2 per rhenium 
complex), and the cells incubated for 30 minutes at 37 °C. The culture medium was 
removed, and the cells were washed twice with PBS. The cells were then fixed by the 
addition of 1 mL of a 4% paraformaldehyde solution in PBS for 15 minutes. After washing 
with PBS, the cells were mounted on glass slides using ProLong® Diamond Antifade 
Mountant (Invitrogen) for imaging. Confocal fluorescence microscopy was performed on 
an Olympus FluoView FV1000 confocal microscope with a 40x or 100x objective, a 458 
nm laser for excitation and the emission filter set to 500-550 nm. 
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Chapter 4 
4 The Development of 99mTc/Re(I) Tricarbonyl [2+1] 
Complexes with Peptides Containing 2,2’-Bipyridine 
Residues as b-Turn Mimics 
4.1 Introduction 
4.1.1 Protein Secondary Structure 
β-Sheets are a common secondary structural motif in proteins, accounting for >30% of all 
protein structures.1 β-sheets are composed of multiple β-strands linked together by 
hydrogen bonds in either a parallel or anti-parallel fashion (Figure 4.1), with the latter being 
more common. Often, β-strands are linked by a U-shaped turn region called a β-hairpin, 
which reverses the overall direction of the peptide strand, arranging them in an anti-parallel 
fashion.  
 
Figure 4.29: Parallel (left) versus anti-parallel (right) β-sheets. 
β-hairpins are important in biological recognition events such as protein-protein and 
protein-peptide interactions.2,3 Their study for the purpose of molecular imaging is 
important, as they could be utilized to target medically relevant biological entities with a 
propensity to interact with β-hairpins. One such example is the peptide T140, which binds 
to the C-X-C chemokine receptor 4 (CXCR4). T140 was derived from the antimicrobial 
self-defense peptides tachyplesin and polyphemusin, which were extracted from the 
hemocytes of horseshoe crabs. Structurally, T140 contains a disulfide bridge that stabilizes 
the anti-parallel β-sheet structure.4 This structure is essential for the peptide’s interaction 
with CXCR4, but the turn region is located outside of the CXCR4 binding pocket.5 
Modification of the turn region has been shown to be possible without affecting the binding 
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of the peptide to the receptor.6,7 Therefore, the development of peptides containing β-
hairpin mimicking structures may help create diagnostic and therapeutic agents for diseases 
involving the CXCR4 receptor such as HIV and cancer. 
4.1.2 Imaging Probe Design: Integrated Versus Pendant 
Metal-based molecular imaging probes require a method of connecting a targeting 
component, such as a peptide, and signaling component, such as a radiometal. This is 
typically done through a metal chelator. Two methodologies are employed when designing 
metal-containing peptide-based imaging probes (Figure 4.2).8 The most common approach 
is the pendant design in which a radiometal is connected to a peptide through a bifunctional 
chelator, which is attached to the peptide either through a modified side-chain, or through 
one of the termini of the peptide, typically through an amide linkage. By this method, the 
metal complex is placed away from the biologically active site. The pendant approach can 
be problematic, as modification of the original peptide may result in decreased affinity for 
the biological target of interest, and removal of the metal complex from the targeting entity 
in vivo can occur by trans-chelation, or enzymatic cleavage. The latter can be mitigated 
through the use of single amino acid chelates (SAAC),9 or through conjugation of the 
complex to the peptide through linkages other than amide bonds; however these do not 
address the issue of decreased affinity to the target of interest. 
 
Figure 4.30: Pendant (left) versus integrated (right) design. 
An integrated approach may be able to remedy these issues. With this approach, the metal 
complex is integrated into the peptide backbone, effectively “hiding” the radiometal within 
the framework of the peptide, resulting in increased stability and making for a more 
compact metal complex. It has been shown that smaller technetium complexes have a 
76 
 
higher likelihood of maintaining the biological activity of the original ligand.10 An example 
of an integrated design is the use of a tridentate 2,6-bis(aminomethyl)pyridine ligand 
coordinated to rhenium and integrated into a macrocyclic peptide structure as a 
replacement for the turn region.11 Integration of the radiometal into the peptide structure 
did not interfere with the already present β-sheet secondary structural elements, effectively 
integrating the metal complex into the β-hairpin mimic, with the potential for applications 
in radiopharmaceuticals. 
4.1.3 2,2’-Bipyridine as a Bidentate Chelator 
Examples in the literature have shown that peptides containing 2,2’-bipyridine (bpy) can 
form β-hairpin structures upon coordination with a metal. A notable example was by 
Schneider and Kelly, in which square planar Cu(II) complexes were used to nucleate β-
hairpin formation.12 Their peptides contain a 6,6’-bis(acylamino)-2,2’-bipyridine residue, 
which exists in a transoid conformation prior to metal coordination (Figure 4.3 – left). 
Upon coordination with Cu(II), the bipyridine residue forms a cisoid structure (Figure 4.3 
– right). This allows for interstrand hydrogen bonds to form, resulting in a β-hairpin 
structure. 
The ability of bipyridine based peptides to complex with a metal and form a β-turn structure 
introduces the possibility of incorporating a radiometal into the peptide structure. Since β-
sheets are important in biological recognition,2 a bipyridine based β-turn peptide labelled 
with a radiometal could allow for their use in nuclear imaging techniques such as SPECT 
or PET for the purpose of imaging cancer and other disease states.  
 
Figure 4.31: Square planar Cu(II) complexes of 2,2’-bipyridine nucleating β-sheet 
formation. 
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There are many examples in the literature of rhenium complexes with bipyridine.13–16 A 
bidentate bipyridine ligand and a monodentate ligand such as pyridine or imidazole can 
form a Re(I) tricarbonyl complex. Isostructural complexes can also be formed with 
technetium-99m to form a radioactive imaging probe. These can be synthesized efficiently 
using a microwave reactor in a one-pot, two-step synthesis (Figure 4.4). 
 
Figure 4.32: Synthesis of isostructural [2+1] complexes of Re and 99mTc. A bidentate 
bipyridine ligand and monodentate pyridine ligand fill the 3 coordination sites on the 
metal center. 
This chapter will focus on the design and synthesis of β-hairpin mimicking peptides 
containing a bidentate 2,2’-bipyridine chelator for the purpose of coordinating Re/99mTc 
towards the development of SPECT imaging agents. The incorporation of a bipyridine 
moiety into a peptide would most easily be accomplished by Fmoc solid-phase peptide 
synthesis (SPPS), therefore requiring the design of an unnatural Fmoc-amino acid 
containing the desired bipyridine moiety (Figure 4.5). After the amino acid has been 
incorporated into the peptide, the structure of the peptide will be evaluated by circular 
dichroism (CD) spectroscopy. The peptide will then be coordinated to Re/99mTc for the 
purpose of nucleating β-sheet formation, and the structure evaluated by CD spectroscopy. 
 
Figure 4.33: Proposed Fmoc-protected 2,2’-bipyridine amino acid. 
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4.2 Results and Discussion 
4.2.1 Synthesis of 3,3’-Diamino-2,2’-Bipyridine Amino Acid 
To synthesize the bipyridine amino acid, 3,3’-diamino-2,2’-bipyridine was used as a 
building block, as the two amino groups could be used for further elaboration. The first 
synthetic approach taken for the synthesis of 3,3’-diamino-2,2’-bipyridine was the 
Ullmann coupling of compound 1 to make the bipyridine 2, followed by hydrolysis of the 
acetyl groups to yield the diamine 3 (Scheme 4.1). In the Ullmann coupling, free amines 
greatly decrease the yield of the desired product, due to the formation of byproducts. 3-
Amino-2-chloropyridine was protected with an acetyl group by dissolving it in neat acetic 
anhydride and stirring overnight. The acetylated product 1 was obtained in an 85% yield. 
Synthetic procedures published in the literature gave a yield of 77% for the Ullmann 
coupling of 1, followed by a 95% yield for the hydrolysis of the acetyl groups.17 However, 
yields obtained from this reaction were quite low. A 27% yield of 2 was obtained on one 
attempt, while all attempts afterwards only yielded recovered starting material. 
 
Scheme 4.3: Initial synthesis of 3,3'-diamino-2,2'-bipyridine. 
The low yields obtained in the coupling reaction can be attributed to the lack of reactivity 
of the starting material. Electron donating groups are typically inhibiting in Ullmann 
couplings. Electron withdrawing groups (EWG) ortho to the halogen are typically 
activating towards the formation of the arylcopper(I) intermediate, accelerating the reaction 
rate and allowing for coupling at lower temperatures.18 A nitro group in the 3-position 
would be ideal as an EWG in this position, as it may be reduced to the amine after 
homocoupling. 3-Nitro-2-chloropyridine was used in the coupling reaction with activated 
bronze powder as the copper source. TLC indicated that the starting material was consumed 
after only 2 hours at 150 °C. After optimization of the reaction and workup conditions, 
yields of 40-48% were obtained. Reduction of the nitro groups was then performed with 
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SnCl2·2H2O at reflux in concentrated HCl. The diamine 3 was obtained in 90-95% yield. 
Formation of the monosuccinamide 5 was achieved by stirring 3 in DCM with succinic 
anhydride in yields ranging from 75-90%. Protection of the amine with an Fmoc group 
gave 6 in 68-72% yield. This novel amino acid was then suitable for use in SPPS. Scheme 
4.2 highlights the synthesis of compound 6. 
 
Scheme 4.4: Synthesis of 3,3'-diamino-2,2'-bipyridine amino acid (6). 
4.2.2 Design of a b-Hairpin Peptide 
Designing a peptide that is optimal for β-hairpin formation is important, as secondary 
structures may not form if the chosen sequence does not stabilize them. Ideally, with a 
peptide containing 2,2’-bipyridine, coordination with a metal such as rhenium or 
technetium-99m should nucleate β-hairpin formation or stabilize already present secondary 
structure. In 1996, Ramírez-Alvarado et al. reported on the design and structural 
characterization of a peptide system optimized to readily undergo β-hairpin formation.19 
Using a program called WHATIF20 and the protein structure database included with the 
program consisting of 279 proteins with less than 50% homology, they determined that 
peptides containing two-residue turns with three-residue strands were most common. They 
developed a peptide designated as BH8, which was shown to form a β-sheet structure by 
NMR and CD spectroscopy in water, and was stabilized in 30% 2,2,2-trifluoroethanol 
(TFE). Residues on the N-terminal end were defined as -B3, -B2 and -B1, while those on 
the C-terminal end were defined as +B1, +B2 and +B3.  
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We elected to use this scaffold in the design of our bipyridine β-hairpin peptide. The 2,2’-
bipyridine based amino acid will emulate the two-residue turn region, with the succinamide 
group on the C-terminal end, and a β-alanine on the N-terminal end, which will allow the 
two strands to align in an anti-parallel fashion. Due to the trans conformation of 2,2’-
bipyridine ligands, the non-coordinated peptide should not contain any ordered secondary 
structure. Metal coordination should induce formation of a β-sheet. The remaining residues 
were mainly chosen due to statistical considerations; however, there were other factors that 
were considered as well. The -B2 and +B2 positions were chosen to be threonine residues, 
as previous work showed that when present together in a non-hydrogen bonded site, they 
had the highest intrinsic propensity of all amino acids for formation of β-hairpins.21 It was 
found that positively charged residues are commonly found in the +B1 position, so lysine 
was chosen for this position. +B3 was chosen to be tyrosine, as aromatic residues were 
found to be quite abundant in that position. Isoleucine and valine were found together at 
the -B3 and -B1 positions respectively, twice as often as random chance might predict. A 
previous study also determined that interactions between tyrosine and isoleucine at the +B3 
and -B3 positions respectively, aided in the stabilization of the β-hairpin when in a 
hydrogen bonded site.22 In order to prevent lateral oligomerization of the peptide strands, 
arginine residues were added to the termini to cause electrostatic repulsion between the 
individual peptide strands. However, this could have the potential side effect of causing 
intrastrand electrostatic repulsion. In order to counteract this, glycine was added as a spacer 
in between the arginine residues and the -B3 and +B3 residues. Since glycine has few 
conformational restrictions, it tends to break secondary structure. This should prevent the 
arginine and glycine residues from forming a part of the β-hairpin structure, reducing the 
repulsion between the two β-strands. The C-terminus of the peptide will also be modified 
with an amide in place of the carboxylic acid in order to improve stability. Figure 4.6 shows 
the peptide BH8 compared to our newly designed bipyridine β-hairpin peptide (7). 
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Figure 4.34: β-Hairpin peptide BH8 (top). 2,2’-Bipyridine β-hairpin peptide 7 (bottom). 
4.2.3 Synthesis of a b-Hairpin Peptide 
Synthesis of the diamino-bipyridine peptide was performed by both manual and automated 
methods. The peptide was built on Rink amide MBHA resin in order to afford an amide 
terminus upon cleavage from the resin. The first five amino acids, KTYGR, were coupled 
by automated synthesis using the microwave reactor in a Biotage Syrowave peptide 
synthesizer. Couplings were all performed at 75 °C through microwave irradiation. 
Compound 6 was coupled manually at room temperature. The bipyridine amino acid was 
poorly soluble in DMF, so N-methylpyrrolidinone (NMP) was used instead. Once this was 
coupled, the remaining amino acids RGITV-(β-Ala) were coupled using the microwave 
reactor. Once cleaved from the resin, the crude peptide was analyzed by HPLC-MS. The 
desired peptide was observed as determined by mass spectrometry; however, there were 
many other species present in the crude product. One of the most prominent side products 
was the peptide containing the first five amino acids plus the bipyridine amino acid. It was 
determined that the amino group on the bipyridine amino acid was less reactive than that 
of a standard amino acid, due to conjugation with the aromatic system. In order to improve 
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the coupling efficiency, Fmoc-β-Ala-OH was coupled twice for 45 minutes at 75 °C in the 
microwave reactor, using HATU as the coupling reagent. After these coupling cycles, 
approximately equal amounts of peptide with and without the β-Ala residue were present. 
After a final coupling at 75 °C for 2 hours, only small amounts of peptide without the β-
Ala residue were observed. Complete coupling was observed with a coupling of 2 hours, 
followed by a second 1-hour coupling, both at 75 °C with HATU as the coupling agent. 
The remainder of the peptide was synthesized using standard protocols. After the peptide 
was cleaved from the resin and purified by reversed-phase HPLC, the pure peptide 7 was 
isolated in 14% yield.  
4.2.4 Structural Evaluation by Circular Dichroism Spectroscopy 
Circular dichroism (CD) spectroscopy was used to evaluate the secondary structure of 
peptide 7 (Figure 4.7).  The UV-CD spectrum was first acquired on peptide 7 in water. A 
negative band was observed with a minimum at 194 nm, which is consistent with a random 
coil structure as was expected for the peptide. A positive band was also observed at <180 
nm. The spectrum was also acquired in 30% TFE, a secondary structure stabilizing solvent, 
to determine if it was possible for secondary structure to form. For a peptide/protein 
containing a β-sheet, a negative band in the 210-220 nm range and a positive band in the 
190-200 nm range are expected, though some variation in these numbers can be expected.23  
A shift of the negative band from 194 nm to 203 nm occurred, and a positive band with a 
maximum of 186 nm was observed. The bands observed in the CD spectrum of 7 in 30% 
TFE suggest the presence of a certain population of peptide folded into a β-sheet structure, 
with the rest existing in a random coil conformation. This indicates that the peptide is 
capable of forming secondary structure. Unfortunately, the effect of rhenium coordination 
on the secondary structure could not be characterized, as the pure complex could not be 
obtained in sufficient quantities, as will be discussed in the next section. 
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Figure 4.35: Circular dichroism spectra of peptide 7 in water (blue) and 30% TFE 
(orange). 
4.2.5 Formation of the [2+1] Rhenium Complex and Radiolabelling 
with Technetium-99m 
Coordination of peptide 7 to rhenium was performed in a one-pot two-step synthesis to 
form the [2+1] complex. First, 7 was reacted with one equivalent of [Re(CO)3(H2O)3]OTf 
under aqueous conditions at 100 °C for 12 minutes under microwave irradiation to form 
Re(CO)3(H2O)(7)+. Some uncoordinated peptide was still observed by HPLC-MS, but 
longer reaction times nor additional equivalents of the rhenium precursor resulted in 
consumption of the peptide. Two peaks of approximately equal intensity were observed in 
the HPLC chromatogram that corresponded to Re(CO)3(H2O)(7)+, resulting from the 
formation of a pair of coordination isomers due to the asymmetric nature of the peptide 
ligand (Figure 4.8). An excess of 4-dimethylaminopyridine (4-DMAP) was added to 
displace the H2O ligand, as 4-DMAP was previously shown to form stable [2+1] rhenium-
bipyridine complexes.24 This step had to be carefully optimized, as long reaction times at 
higher temperatures (100 °C) resulted in 4-DMAP displacing 7 to form Re(CO)3(4-
DMAP)3+, while low temperatures (40 °C) and shorter reaction times resulted in 
incomplete formation of the desired Re(CO)3(4-DMAP)(7)+. Nearly complete conversion 
was observed when the reaction was performed at 75 °C for 45 minutes. 
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Figure 4.36: Coordination of peptide 7 and 4-DMAP with rhenium to form a [2+1] 
chelation system. 
Purification of the complex was attempted by solid-phase extraction on a Waters C-18 Sep-
pack. While this was successful in removing remaining 4-DMAP, it was unable to remove 
Re(CO)3(4-DMAP)3+ resulting from the reaction of 4-DMAP with unreacted 
[Re(CO)3(H2O)3]OTf. Purification was then attempted by preparative HPLC. However, 
this was also unsuccessful in removing Re(CO)3(4-DMAP)3+ as well as uncoordinated 4-
DMAP. It was also noted that upon standing in solution at room temperature, an increase 
in the amount of uncoordinated peptide was observed over time due to displacement of the 
peptide by the solvent. Previous reports suggest that 3,3’-disubstituted 2,2’-bipyridine 
ligands form a twisted geometry upon metal coordination due to steric clash of the 3,3’ 
substituents, preventing the pyridyl rings from forming a planar geometry.17 This is likely 
exacerbated by the long peptide strands in 7, causing instability of the metal complex. 
Isolation of the pure peptide metal complex was not possible due to its instability. Attempts 
to radiolabel the peptide with technetium-99m gave similar results as for coordination to 
rhenium (Figure 4.9). Analysis by radio-UHPLC showed a peak corresponding to the [2+1] 
technetium-99m complex with 7 and 4-DMAP as observed by comparison to the retention 
time of the rhenium complex. Numerous other peaks were observed as well, including one 
corresponding to the [99mTc]Tc(CO)3(4-DMAP)3+ complex. 
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Figure 4.37: UHPLC chromatograms of the Re coordinated peptide 7 (top) and 99mTc-
labelled peptide 7 (bottom). 
4.3 Conclusions 
A novel Fmoc-protected amino acid containing a 2,2’-bipyridine residue (compound 6) 
was synthesized in four steps from 3-nitro-2-chloropyridine. The amino acid was 
incorporated into a peptide (peptide 7) by solid-phase peptide synthesis. Analysis by CD 
spectroscopy confirmed that the peptide exists in a disordered structure but can fold into a 
structure resembling a β-sheet in 30% TFE. Coordination of the peptide to Re/99mTc in a 
[2+1] fashion yields unstable complexes that were unable to be purified. While peptides 
containing the bipyridine amino acid (6) are not suitable for coordination to Re/99mTc for 
the purpose of developing molecular imaging agents, they may be more suitable for 
applications such as metal ion sensing where isolation of the formed peptide metal complex 
is not necessary. Alternatively, amino acids containing 4,4’-disubstituted bipyridines may 
allow for the formation of more stable complexes with Re/99mTc. 
4.4 Experimental 
General Procedures and Materials: All reagents and solvents were purchased from 
commercial sources and used without further purification unless otherwise stated. NMR 
spectra were recorded on either an Agilent Mercury VX 400 or Inova 400. All chemical 
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shifts are reported in ppm and referenced to the residual solvent peaks. Circular dichroism 
spectra were obtained on a Jasco J-810 circular dichroism spectropolarimeter. 
Manual Peptide Synthesis: Fully protected resin bound peptides were synthesized by 
standard Fmoc solid phase peptide synthesis methods. Fmoc protected Rink amide MBHA 
resin (loading 0.34 mmol/g or 0.54 mmol/g) was employed as the solid support. Resin was 
swollen by suspension in DCM for 15 minutes. Fmoc deprotection was achieved using 
20% piperidine in DMF over two cycles (2 minutes, then 15 minutes). Amino acids were 
pre-activated for 5 minutes using 3 equivalents of the Fmoc protected amino acid with 3 
equivalents of either HCTU or HATU and 6 equivalents of DIPEA (N,N-
diisopropylethylamine) in DMF. The activated ester was added to the resin and coupling 
was performed over 60 minutes. The resin was washed consecutively with DMF then 
DCM. Cleavage of the side chain protecting groups and the peptides from the resin was 
performed using 95% (v/v) TFA, 2.5% (v/v) TIPS and 2.5% (v/v) H2O over a period of 3-
4 hours. The peptides were precipitated from solution with tert-butylmethyl ether (TBME) 
and centrifuged for 5 minutes at 3000 rpm. After decanting of the mother liquor, addition 
of TBME was repeated and the peptide centrifuged again. H2O was then added, the solution 
frozen at -78 °C and lyophilized. 
Automated Peptide Synthesis: Automated peptide synthesis was performed using a 
Biotage Syrowave automated microwave peptide synthesizer. Fmoc protected Rink amide 
MBHA resin (loading 0.34 mmol/g or 0.54 mmol/g) was employed as the solid support. 
Resin was swollen by suspending in DCM for 15 minutes prior to inserting the resin into 
the automated synthesizer. Fmoc deprotection was achieved by addition of a 40% solution 
of piperidine in DMF over two cycles (30 seconds and 12 minutes). Fmoc protected amino 
acids were coupled by addition of 4 equivalents of Fmoc protected amino acid in DMF, 4 
equivalents of HCTU in DMF and 8 equivalents of DIPEA in NMP (N-methyl 
pyrrolidinone). Couplings were performed over 5 minutes at 75 °C by microwave 
irradiation. More difficult couplings were performed using HATU with longer periods of 
microwave irradiation. Resin cleavage and purification were performed as per manual 
peptide synthesis. 
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Purification by Reversed-Phase HPLC-MS: Reactions were analyzed using reversed-
phase analytical HPLC-MS (Agilent Zorbax SB-C18 Column, 5 µm, 4.6 x 150 mm). The 
setup consisted of a Waters 600 controller, Waters prep degasser and Waters Mass Lynx 
software. The gradient solvent system comprised of solvent A (H2O+0.1%TFA) and 
solvent B (ACN + 0.1%TFA) at a flow rate of 1.5 mL/min over 10 minutes with a 5-minute 
wash cycle at 95% solvent B. The UV absorbance was detected using a Waters 2998 
photodiode array detector. Peptides were purified using reverse phase preparative HPLC 
column (Agilent Zorbax PrepHT SB-C18 Column, 5 µm, 21.2 x 150 mm). The flow rate 
for preparative HPLC was 20 mL/min. After purification, the collected fractions were 
frozen at -78 °C, lyophilized and analyzed by reversed-phase analytical HPLC-MS. 
3-acetylamino-2-chloropyridine (1): Compound 1 was synthesized by a published 
method from 3-amino-2-chloropyridine (5 g, 38.9 mmol,) and Ac2O (50 mL).17 The pure 
acetylated product was collected as colourless needles (5.6 g, 85%). 1H NMR (400 MHz, 
CDCl3): δ = 8.71 (dd, J = 8.2 Hz, J = 1.7 Hz, 1 H), 8.10 (dd, J = 4.7 Hz, 1 H), 7.65 (br. s, 1 
H), 7.26 (dd, J = 8.2 Hz, J = 4.7 Hz, 1 H), 2.27 (s, 3 H). 13C NMR (100 MHz, CDCl3) δ = 
186.8, 143.8, 139.8, 131.9, 129.3, 123.3, 24.8. MS (ESI+): m/z calculated C7H8ClN2O+ 
[M+H]+  171.0; found 171.0. 
3,3'-diacetylamino-2,2'-bipyridine (2): Compound 2 was synthesized by a modification 
of a published procedure.17 Bronze powder (10 g) was activated by stirring in 100 mL of a 
2% solution of I2 in acetone for 15 minutes. After filtration, the solid was then treated with 
10 mL conc. HCl in 90 mL of acetone for 15 minutes. After filtration and rinsing with 
acetone, the bronze powder was dried under high vacuum and then used immediately. 
Compound 1 (4.1 g, 24 mmol) was dissolved in dry DMF (25 mL) under N2 atmosphere. 
Activated bronze powder (4.0 g, 63 mmol) was suspended in the solution, and heated to 
110 °C for 24 hours. The reaction was quenched by the addition of 20 mL of H2O. The 
resulting grey solid was filtered, washed with 20 mL H2O, 40 mL conc. NH4OH and then 
an additional 20 mL of H2O. The grey cake was suspended in 100 mL of DCM and stirred 
vigorously. After filtration, the solvent was removed, and the pure product was isolated as 
an off-white solid (0.91g, 27 %). 1H NMR (400 MHz, CDCl3) δ = 9.08 (d, J = 8.3 Hz, 2 
H), 8.32 (d, J = 4.2 Hz, 2 H), 7.36 (dd, J = 8.5 Hz, J = 4.6 Hz, 2 H), 2.23 (s, 6 H). 13C NMR 
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(100 MHz, CDCl3) δ = 169.3, 141.9, 140.4, 136.6, 129.9, 124.0, 25.5. MS (ESI+): m/z 
calculated C14H15N4O2+ [M+H]+ 271.1; found 271.1. 
3,3'-diamino-2,2'-bipyridine (3)  
Method A: Compound 3 was synthesized by a published procedure from compound 2 (0.9 
g, 3.29 mmol).17 The product was isolated as a bright yellow solid (0.47 g, 77%). 1H NMR 
(400 MHz, CDCl3): δ = 7.98 (dd, J = 4 Hz, J = 2.1 Hz, 2 H), 7.04 (m, 4 H), 6.28 (br. s, 4 
H). 13C NMR (100 MHz, CDCl3): δ 143.8, 140.6, 135.8, 124.0, 123.0. MS (ESI+): m/z 
calculated C10H11N4+ [M+H]+ 187.1; found 187.1. 
Method B: Compound 3 was synthesized from compound 4 (3 g, 12.2 mmol) by a 
published procedure.17 The pure product was isolated as a bright yellow solid (2.1 g, 93 
%). 
3,3'-dinitro-2,2'-bipyridine (4): Compound 4 was synthesized by modification of a 
published procedure.17 Activated bronze powder (10 g, 157.4 mmol) was suspended in a 
solution of 3-nitro-2-chloropyridine (10 g, 63.3 mmol) in 120 mL of dry DMF under N2. 
The mixture was heated to 150 °C for 3.5 hours, at which point no more starting material 
was observed as indicated by TLC. The hot reaction mixture was then filtered over Celite. 
40 mL of conc. NH4OH and 40 mL H2O was added to the resulting solution which was 
then extracted multiple times with EtOAc. The combined organic layers were dried over 
Na2SO4 and concentrated under reduced pressure until all of the EtOAc was removed and 
only DMF was left. Approximately 100 mL of H2O was added to precipitate the crude 
product, which was collected by vacuum filtration. The pure product was obtained as a 
golden yellow solid by recrystallization from EtOH (3.23 g, 41%). 1H NMR (400 MHz, 
CDCl3): δ = 8.88 (dd, J = 4.8 Hz, J = 1.5 Hz, 2 H), 8.59 (dd, J = 8.4 Hz, J = 1.5 Hz, 2 H), 
7.65 (dd, J = 8.4 Hz, J = 4.8 Hz, 2 H). 13C NMR (100 MHz, CDCl3) δ 153.1, 151.4, 143.9, 
133.0, 124.2. MS (ESI+): m/z calculated C10H7N4O4+ [M+H]+ 247.0; found 247.0. 
4-((3'-amino-[2,2'-bipyridin]-3-yl)amino)-4-oxobutanoic acid (H-Bpy-Suc-OH) (5): 
Compound 3 (2 g, 10.75 mmol) was dissolved in DCM (40 mL) and succinic anhydride 
was added (1.08 g, 10.75 mmol). After a few moments of stirring at room temperature the 
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product began to precipitate. After 45 minutes, the reaction mixture was filtered by vacuum 
filtration to yield the pure product as a yellow solid (2.67g, 87%). 1H NMR (400 MHz, 
DMSO-d6)  δ = 12.16 (br. s, 1 H), 8.85 (dd, J = 8.4 Hz, J = 1.6 Hz, 1 H), 8.28 (dd, J = 4.6 
Hz, J = 1.6 Hz, 1 H), 7.91 (dd, J = 4.3 Hz, J = 1.6 Hz, 1 H), 7.29 (dd, J = 8.4 Hz, J = 4.6 
Hz, 1 H), 7.26 (dd, J = 8.4 Hz, J = 1.6 Hz, 1 H) 7.15 (dd, J = 8.4 Hz, J = 4.3 Hz, 1 H), 2.58 
(m, 4 H). 13C NMR (100 MHz, DMSO-d6) δ = 174.1, 170.9, 146.1, 143.4, 141.2, 136.9, 
135.4, 128.1, 125.2, 124.8, 122.7, 32.8, 29.2. MS (ESI+): m/z calculated C14H15N4O3+ 
[M+H]+ 287.1; found 287.1. 
4-((3'-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-[2,2'-bipyridin]-3-yl)amino)-4-
oxobutanoic acid (Fmoc-Bpy-Suc-OH) (6): Compound 5 (2.5 g, 8.74 mmol) was 
dissolved in a solution of NaHCO3 (2.2 g, 26.2 mmol) in H2O (150 mL) and cooled to 0 
°C in an ice bath. Fmoc-Cl (3.38 g, 13.1 mmol) was added dropwise as a solution in 1,4-
dioxane over a period of 1 hour. The solution was warmed to room temperature and stirred 
overnight. The pH of the solution was adjusted to 1 with concentrated HCl. The resulting 
solid was filtered off and recrystallized from toluene to give the pure product as an off-
white solid (2.39 g, 68%). 1H NMR (400 MHz, DMSO-d6) δ = 12.64 (s, 1 H), 12.23 (s, 1 
H), 12.16 (s, 1 H), 8.87 (dd, J = 8.5, 1.6 Hz, 1 H), 8.48 (d, J = 8.6 Hz, 1 H), 8.37 (dd, J = 
4.6 Hz, J = 1.6 Hz, 1 H), 8.27 (dd, J = 4.6, J = 1.6 Hz, 1 H), 7.83 (d, J = 7.5 Hz, 2 H), 7.61 
(d, J = 7.4 Hz, 2 H), 7.49 (dd, J = 8.5, J = 4.6 Hz, 1 H), 7.44 (dd, J = 8.5, J = 4.6 Hz, 1 H), 
7.35 (t, J = 7.4 Hz, 2 H), 7.27 (t, J = 7.4 Hz, 1 H), 4.40 (d, J = 6.9 Hz, 2 H), 4.27 (t, J = 6.8 
Hz, 1 H), 2.61 (t, J = 6.6 Hz, 2 H), 2.51 (t, J = 6.9 Hz, 2 H). 13C NMR (100 MHz, DMSO-
d6) δ = 173.99, 171.08, 153.36, 144.02, 142.03, 141.84, 141.38, 141.21, 136.18, 136.00, 
129.97, 128.82, 128.11, 127.52, 125.47, 124.70, 120.60, 120.54, 110.81, 66.77, 46.85, 
32.60, 29.16. MS (ESI+): m/z calculated C29H25N4O5+ [M+H]+ 509.2; found 509.1. 
H-Arg-Gly-Ile-Thr-Val-(β-Ala)-(Bpy-Suc)-Lys-Thr-Tyr-Gly-Arg-NH2 (7): The 
peptide was synthesized and isolated by standard automated methods. Fmoc-β-Ala-OH 
was coupled twice at 75 °C under microwave irradiation for 2 hours and 1 hour, 
respectively. Purification was performed by preparative reversed-phase HPLC (17% to 
50% ACN/H2O + 0.1% TFA). The peptide was obtained as a white powder (20.4 mg, 14%). 
MS (ESI+): m/z calculated for C67H106N23O16+ [M+H]+ 1488.8; found 1488.7. 
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Chapter 5 
5 Amino-Substituted 2,2’-Bipyridine Ligands as 
Fluorescent Indicators for Zn(II) and Applications for 
Fluorescence Imaging of Prostate Cells 
5.1 Introduction 
As a divalent cation, zinc has several biological functions including storage and secretion 
of insulin from pancreatic beta cells,1 and the maintenance of prostate health through 
various mechanisms such as suppression of overall energy production, controlling 
apoptosis, and suppressing tumor progression.2–6 The prostate has been shown to have the 
highest Zn(II) concentration of any soft tissue.7 Downregulation of zinc transporters in 
cancerous prostate tissue results in greatly reduced levels of Zn(II) in comparison to healthy 
prostate tissue.2,3 In contrast, in benign prostatic hyperplasia (BPH) Zn(II) levels are 
maintained.8 To this end, Zn(II) has garnered much interest as a potential biomarker of 
prostate cancer (PCa) and may be useful in differentiating malignant tissue from healthy 
and benign tissue.9,10 Fluorescence has become the foremost method for the detection of 
Zn(II) in biological systems, as Zn(II) ions are unresponsive to other analytical techniques 
due to its electronic nature. Fluorescence offers the flexibility for use in in vitro biological 
assays and cellular imaging by fluorescence microscopy. A 3-hydroxychromone based 
fluorescent Zn(II) sensor has recently shown promise for differentiating PCa cells from 
normal prostate epithelial cells in vitro.11 
Fluorescence of ligands coordinated to Zn(II) may be modulated by a variety of 
mechanisms,12 including intramolecular charge transfer (ICT),13,14 photo-induced electron 
transfer (PeT)15–17 and excited-state intramolecular proton transfer (ESIPT).11,18 
Fluorescent ICT agents have been used extensively as sensors for a wide variety of metal 
ions. An ICT fluorophore is an organic ligand containing a conjugated electron donor and 
acceptor which undergo charge separation upon photoexcitation.19 Upon binding of Zn(II) 
to either the electron donor or acceptor sites, the fluorescence excitation and emission 
wavelengths shift, giving a fluorescent signal unique to Zn(II). Substituted 2,2’-bipyridine 
ligands have shown great promise as Zn(II) sensors.14,18,20–23 When substituted with 
electron donating groups, the imine nitrogen atoms act as electron acceptors. Coordination 
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of Zn(II) at the acceptor site causes a bathochromic shift of excitation and emission due to 
stabilization of the excited state. 
In this work, we have prepared several derivatives of 2,2’-bipyridine with electron-
donating amine substituents (Figure 5.1). In order to determine the characteristics that 
make for an optimal fluorescent Zn(II) indicator, we have characterized the UV/Vis 
absorption and fluorescence properties of the ligands, and changes in these properties upon 
coordination to Zn(II). We have also applied this knowledge to Zn(II) sensing in a 
biological system by comparing the ability of two of the ligands to differentiate PCa cells 
from BPH cells by Zn(II) mediated fluorescence. 
 
Figure 5.38: Amine substituted 2,2’-bipyridine ligands. 
5.2 Results and Discussion 
5.2.1 Synthesis 
Five amine-substituted bipyridine ligands were synthesized for evaluation as fluorescent 
Zn(II) sensors (Figure 5.1). The series of five ligands were chosen to compare compounds 
with differing excited states, and different strengths of electron donating substituents to 
determine the characteristics best suited for Zn(II) sensing in a biological system. 
Compounds 1 and 2 were synthesized by previously reported methods.24,25 Scheme 5.1 
highlights the syntheses of compounds 4, 6, and 7. Compound 4 was synthesized in 25% 
yield by a ligand-free Ni(II) catalyzed coupling reaction26 from compound 3, which was 
synthesized by Suzuki-Miyaura coupling of 5-bromo-2-chloropyridine with 4-
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aminophenylboronic acid pinacol ester. Compound 6 was synthesized in two steps from 
5,5’-dimethyl-2,2’-bipyridine, which was oxidized with potassium permanganate by a 
previously reported protocol to form the diacid 5,27 which then underwent a condensation 
reaction with o-phenylenediamine in polyphosphoric acid to form the benzimidazole 6 in 
75% yield. Methylation of 6 with methyl iodide gave compound 7 in a moderate 43% yield. 
 
Scheme 5.5: Syntheses of bipyridine derivatives 4, 6 and 7. 
5.2.2 UV/Vis Absorption Studies 
5.2.2.1 Solvent Polarity Effects 
The effects of solvent polarity on the UV/Vis absorption spectra were determined for the 
bipyridine ligands to aid in characterizing the excited state. The UV/Vis spectra of 1 in n-
hexane, n-dodecane and acetonitrile had previously been reported by Glasbeek and Toele.28 
They described two strong absorption bands around 370 nm and 265 nm corresponding to 
S0®S1 and S0®S2 transitions respectively, with maxima that were insensitive to solvent 
polarity. The S0®S1 transition was shown to primarily involve p ® p* HOMO-LUMO 
transitions of the bipyridine group. We observed similar results in methanol for compound 
1 (Table 5.1) with two absorption bands appearing at 364 nm and 265 nm.  
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Table 5.3: UV/Vs absorption characteristics of bipyridine ligands and their Zn(II) 
complexes in methanol. 
 lAbs [nm] e [L×mol-1cm-1] 
1 364, 265 9000, 15000  
2 326, 285  19500, 19000 
4 355 28500 
6 356 42000 
7 334 43000 
Zn-1[a] 366, 265 9500, 14000 
Zn-2 375, 313 14000, 22500 
Zn-4 405 28000 
Zn-6 365 30000 
Zn-7 345 34500 
[a]In the presence of 30 equivalents of ZnSO4. 
Compound 2 also showed two absorption bands, one centered  around 325 nm and the other 
around 290 nm. The UV/Vis absorption spectra were taken in a range of solvents with 
different polarities to help determine the excited state characteristics. The absorption 
maxima for both bands showed a slight dependence on solvent polarity (Table 5.2), with 
polar solvents displaying a lower energy absorption than non-polar solvents (330 and 295 
nm in DMSO versus 316 and 284 nm in cyclohexane). This positive solvatochromism is 
characteristic of an N ® p* ICT excited state. Figure 5.2 depicts the ICT excited state of 
compound 2. The S0®S1 transition is of a higher energy than for compound 1 likely due to 
the lack of intramolecular hydrogen bonding in compound 2. 
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Figure 5.39:  Proposed ICT excited state of compound 2. 
Table 5.4: Photophysical properties of compound 2 (20 µM) in various solvents.[a] Only 
the lowest energy absorption band is shown for clarity. 
 CyH DX CHCl3 DCM EtOH MeOH CH3CN DMF DMSO 
e 2.02 2.22 4.81 8.93 25.3 33 36.6 38.3 47.2 
lAbs 
[nm] 
316 323 320 320 328 326 322 330 331 
lEx 
[nm] 
333 335 336 324 335 337 325 336 339 
lEm 
[nm] 
375 386 396 383 405 406 392 400 405 
SS 
[cm-1] 
3363 3944 4509 4755 5159 5043 5259 4762 4807 
 [a]Abbreviations: CyH, cyclohexane; DX, 1,4-dioxane; CHCl3, chloroform; DCM, 
dichloromethane; EtOH, ethanol; MeOH, methanol; CH3CN, acetonitrile; DMF, N,N-
dimethylformamide; DMSO, dimethylsulfoxide; e, solvent dielectric constant; SS, Stoke’s 
Shift (𝜐"# − 𝜐"%). 
Compound 4 showed a lower energy absorption band in comparison to compound 2 due to 
extended conjugation of the aromatic system. A single broad absorption band was observed 
around 360 nm. Compound 4 displayed strongly positive solvatochromism of the 
absorption band (Figure 5.3) in comparison to 2, likely due to increased charge separation 
in the excited state of the molecule. In cyclohexane, the absorption maximum appears at 
342 nm but is significantly red shifted to 375 nm in DMSO (Table 5.3). 
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Figure 5.40: UV/Vis absorption spectra of compound 4 in (A) non-polar and (B) polar 
solvents. 
Table 5.5: Photophysical properties of compound 4 (20 µM) in various solvents. 
 CyH DX CHCl3 DCM EtOH MeOH CH3CN DMF DMSO 
e 2.02 2.22 4.81 8.93 25.3 33 36.6 38.3 47.2 
lAbs [nm] 342 354 349 350 359 357 356 370 375 
lEx [nm] 342 358 351 351 374 360 369 371 379 
lEm [nm] 402 423 436 436 498 514 482 484 493 
SS [cm-1] 4364 4292 5554 5554 6658 8323 6353 6293 6101 
UV/Vis spectra were not obtainable in the full range of solvents for compound 6 due to 
poor solubility, however, synthesis of the N,N’-dimethylated derivative 7 allowed for 
studies in the full range (Table 5.4, See Appendix C, Table C1 for compound 6 data). Little 
solvatochromism was observed in the absorption spectra for both compounds. This is likely 
due to the weaker electron donating ability of the benzimidazole groups in comparison to 
the amino and aminophenyl substituents of 2 and 4, resulting in a smaller degree of charge 
separation in the excited state. This effect was also observed by Zhu et al. when altering 
the electron donating ability of aryl groups on their 5-arylvinyl-5’-methyl-2,2’-bipyridyl 
(AVMB) fluorophores.14 Lack of solvatochromism in the absorption spectrum does not 
necessarily indicate a lack of ICT. 
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Table 5.6: Photophysical properties of compound 7 (20 µM) in various solvents. 
 CyH DX CHCl3 DCM EtOH MeOH CH3CN DMF DMSO 
e 2.02 2.22 4.81 8.93 25.3 33 36.6 38.3 47.2 
lAbs [nm] 343 343 340 340 336 334 337 343 344 
lEx [nm] 349 351 350 348 351 346 333 356 354 
lEm [nm] 405 415 417 418 429 438 407 427 431 
SS [cm-1] 3962 4394 4591 4812 5180 6071 5460 4671 5047 
5.2.2.2 Zinc Titration 
The ligands were then titrated with ZnSO4 in methanol to determine the changes in the 
UV/Vis absorption spectrum over a range of Zn(II) concentrations. This also aids in 
characterizing the excited state of the molecules. If an ICT character is observed, a 
bathochromic shift of the absorption spectrum is expected upon Zn(II) coordination. 
Ideally, the absorption spectrum of the Zn(II) complex should be in the visible portion of 
the electromagnetic spectrum (greater than 400 nm) for use as a Zn(II) indicator in 
biological systems and for imaging by confocal microscopy. This is because fluorescence 
excitation in the UV region is prone to causing autofluorescence, and can be damaging to 
live cells in imaging experiments. As well, many confocal microscopes are only compatible 
with excitation wavelengths at 405 nm or greater. 
Titration of compound 1 with ZnSO4 in methanol (0.1-30 equivalents) showed very little 
change in the absorption spectrum (Figure 5.4A). The molar absorption coefficient of the 
lowest energy band showed a slight increase, while that of the highest energy band 
decreased slightly. The lowest energy band showed a slight red shift (Table 5.1). Zn(II) 
coordination would likely not stabilize the excited state of compound 1 due to the lack of 
ICT character, therefore showing little change in the absorption characteristics. The 
absorption spectrum of the Zn(II) complex is mostly at wavelengths less than 405 nm, so 
this ligand is not ideal for imaging by confocal microscopy 
In contrast to compound 1, compound 2 showed a large change in the spectrum upon the 
addition of even 0.1 equivalents of ZnSO4 in methanol (Figure 5.4B). Absorption bands 
with maxima at 326 nm and 285 nm both showed large bathochromic shifts to 375 nm and 
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313 nm respectively. Bathochromic shifts of the absorption spectra upon binding to a 
cationic species are indicative of an ICT excited state. However, further addition of Zn(II), 
from 0.2 up to 30 equivalents, did not result in further changes to the absorption maxima, 
and only a slight increase to the molar extinction coefficients was observed up to the 
addition of 5 equivalents of Zn(II). With an absorption spectrum entirely below 405 nm, 
compound 2 is also not ideal for Zn(II) sensing in biological systems. 
Titration of compound 4 with ZnSO4 in methanol resulted in a bathochromic shift of the 
absorption maximum from 355 nm to 405 nm (Figure 5.4C), also indicating an ICT excited 
state. More subtle transitions in the absorption spectrum were observed for 4 in comparison 
to 2, with the most significant changes occuring upon the addition of 0.1-1 equivalents of 
Zn(II), and no further changes occuring after the addition of 5 equivalents. With the Zn(II) 
complex of compound 4 having an absorption maximum at 405 nm, it may be suitable for 
imaging cellular Zn(II). 
Both compounds 6 and 7 showed very subtle changes to the absorption wavelengths upon 
titration with ZnSO4 in methanol (Figure 5.4D and 5.4E), in contrast to the sharp changes 
observed in compounds 2 and 4. For both compounds, 30 equivalents of Zn(II) were 
required before no further changes were observed. The Zn(II) complexes show significant 
absorption at 405 nm. While this is not near the absorption maximum for either compound, 
it is likely to be sufficient for detecting fluorescence from intracellular Zn(II). As 
compound 6 has a stronger absorption at 405 nm upon coordination to Zn(II) in comparison 
to compound 7, it may be more suitable for the detection of intracellular Zn(II). 
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Figure 5.41: UV/Vis absorption spectra of compound 1 (20 µM) (A) compound 2 (B) 
compound 4 (C) compound 6 (D)  and compound 7 (E) at a concentration of 20 µM in 
methanol upon titration with ZnSO4 (0.1-1 equivalents in intervals of 0.1 equivalents, then 
2, 3, 5, 10, 20 and 30 equivalents). 
5.2.3 Fluorescence Studies 
5.2.3.1 Solvent Polarity Effects 
The fluorescence emission spectra of compound 1 in n-hexane, n-dodecane and acetonitrile 
were previously reported by Glasbeek and Toele,28 showing two emission bands in the 
steady-state emission spectra. A higher energy emission around 425 nm corresponds to the 
excited Franck-Condon state, and a lower energy emission around 585 nm results from an 
excited state intramolecular double proton transfer (ESIDPT), with subsequent emission 
from the tautomeric state. Solutions of compound 1 in methanol were also observed to be 
weakly fluorescent. However, only a single emission band was observed at 425 nm. It is 
known that ESIPT is less favourable in polar solvents, which could result in weaker or 
absent emission from the tautomeric form of the molecule in methanol.  
For compound 2, 40 µM of N,N’-diisopropylethylamine (DIPEA) was added to each 
solution for the fluorimetry experiments, as in certain solvents (DX, CHCl3, DCM and 
MeOH) a second excitation and emission band was observed corresponding to the 
protonated form of the molecule due to traces of acid present in these solvents. The addition 
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of DIPEA caused these bands to disappear. The addition of acid in methanol caused the 
first emission band to disappear, and the second emission band to increase in intensity (See 
Appendix D, Figure D14). This evidence supports that the second band is from the 
protonated species. Compound 2 displayed solvatofluorochromism, with emission maxima 
ranging from 375 nm in cyclohexane to 405 nm in DMSO (Table 5.2) indicative of an ICT 
excited state. 
Compound 4 displayed a high degree of positive emission solvatofluorochromism (Table 
5.3), suggesting a polar emissive excited state. In non-polar solvents, emission maxima 
were at 402 nm in cyclohexane and 423 nm in 1,4-dioxane and Stokes shifts were relatively 
small. In cyclohexane, the emission band has some vibronic band structure which is 
indicative of a locally excited state.19 With a slight increase in solvent polarity, the band 
becomes more rounded and unstructured, indicating a shift to a solvent stabilized ICT state. 
This is consistent with the observations made by Zhu et al. for an ICT excited state with a 
strongly donating amino group. In polar aprotic solvents, Stokes shifts were greater than in 
non-polar solvents and emission maxima were shifted to 482-493 nm (Figure 5.5). In polar 
protic solvents, methanol and ethanol, Stokes shifts were much greater, and emission 
maxima were observed at 514 and 498 nm respectively. Stokes shifts for compound 4 were 
also greater than those observed for compound 2, likely due to greater solvent interactions 
in polar solvents. 
 
Figure 5.42: Fluorescence emission spectra of compound 4 in a range of solvents. 
Compounds 6 and 7 (Table 5.4) also showed positive solvatofluorochromism. Stokes shifts 
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were generally smaller in comparison to compound 4, due to the weaker electron donating 
nature of the benzimidazole. Compound 6 showed structured vibronic bands in 1,4-dioxane 
and chloroform, while compound 7 additionally showed structured bands in cyclohexane 
(See Appendix D, Figure D13). Compound 7 displayed greater Stokes shifts than 
compound 6 in all cases. 
For qualitative comparison of the excited-state dipole moments, the Stokes shifts of 
compounds 2, 4 and 7 were plotted against the orientation polarizabilities of the solvents 
to afford the Lippert plots (Figure 5.6). While the linearity of the plots is generally poor 
due to specific solvent interactions (such as hydrogen bonding, and locally excited versus 
charge transfer excited states) causing deviation from the Lippert-Mataga model,19 a 
correlation between solvent polarity and Stokes shift is observed. The slope of the Lippert 
plot of compound 4 is certainly greater than that of compounds 2 and 7, indicating a higher 
degree of polarization in the excited state due to the presence of stronger electron donating 
groups.  
 
Figure 5.43: Lippert plots of compound 2 (orange), compound 4 (blue) and compound 7 
(green). 
5.2.3.2 Zinc Titration and Quantum Yield 
A change in either the intensity of the fluorescence emission, or the emission wavelength 
upon Zn(II) coordination is essential for being able to differentiate fluorescence from the 
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free ligand to that of the Zn(II) complex. A high quantum yield for the Zn(II) complex is 
also essential in order to have a detectable fluorescence signal. 
In stark contrast to the UV-Vis absorption spectrum, the fluorescence wavelengths of 1 
undergo significant change upon the addition of Zn(II). The excitation and emission 
maxima both undergo a bathochromic shift, however, the Stokes shift decreases slightly. 
The emission intensity was also very sensitive to the number of equivalents of Zn(II), with 
very subtle changes occuring upon the addition of up to 30 equivalents of the metal ion 
(Figure 5.7A). Glasbeek and Toele28 estimated that quantum yields for compound 1 were 
on the order of 10-5 in n-hexane, n-dodecane and acetonitrile.  
While we have found a rather low quantum yield for 1 in this study as well, a drastic 70-
fold increase in the quantum yield was observed upon coordination to Zn(II) in aerated 
methanol (Table 5.5). This fluorescence enhancement is likely due to the suppression of 
quenching pathways observed in the free ligand by restricting rotation and by removing 
the intramolecular hydrogen bonding. While this fluorescence enhancement is certainly 
desirable for a Zn(II) indicator, the absorption spectrum is primarily in the UV region. 
Further elaboration of this ligand to decrease the excitation energy may result in a Zn(II) 
sensor suitable for cell imaging by confocal microscopy.  
 
Figure 5.44: Fluorescence emission spectra of compound 1 (A) compound 2 (B) 
compound 4 (C) compound 6 (D) and compound 7 (E) at a concentration of 20 µM in 
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methanol upon titration with ZnSO4 (0.2-1 equivalents in intervals of 0.2 equivalents, then 
2, 3, 5, 10, 20 and 30 equivalents). 
Table 5.7: Fluorescence properties of the bipyridine ligands and their Zn(II) complexes 
in methanol. 
 lEx [nm] lEm [nm] SS [cm-1] [a]ff 
1 342 425 5710 0.0027 
2 337 406 5043 0.058 
4 360 514 8323 0.07 
6 358 433 4838 0.93 
7 346 438 6071 0.92 
Zn-1[b] 366 442 4698 0.19 
Zn-2 377 422 2829 0.18 
Zn-4 406 583 7478 0.0097 
Zn-6 371 471 5723 0.71 
Zn-7 351 481 7700 0.36 
[a]Aerated methanol, compared to quinine sulfate in 0.05 M H2SO4 (f = 0.52)29 [b]In the 
presence of 30 equivalents of ZnSO4. 
As with the absorption spectrum for compound 2, the fluorescence emission spectrum 
showed a sharp change upon the addition of 0.2 equivalents of Zn(II) in methanol. The 
emission band was bathochromically shifted from 406 nm to 422 nm. Further addition of 
Zn(II) resulted in an increase in the emission intensity, with no changes observed after the 
addition of 5 equivalents (Figure 5.7B). As with the absorption spectrum for the Zn(II) 
complex, two excitation maxima were observed at 380 and 320 nm. The quantum yield of 
compound 2 was higher than for that of compound 1 (Table 5.5). However, the Zn(II) 
complex of compound 2 had a remarkably similar quantum yield to that of the Zn(II) 
complex of compound 1, giving only a 3-fold increase. A decrease in the Stokes shift was 
also observed for the Zn(II) complex of compound 2. While compound 2 was responsive 
to Zn(II) concentration, absorption in the UV range prevents its use in Zn(II) sensing in 
biological systems.  
The quantum yield for compound 4 was similar to that of compound 2 in aerated methanol 
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(Table 5.5). We had hoped that a similar increase in quantum yield would be observed for 
compound 4 as well upon Zn(II) coordination, however, the Zn(II) complex of compound 
4 showed significantly quenched fluorescence. This finding is in agreement with other 
ligands containing strongly electron donating amino groups such as aminophenyl-
substituted AVMBs14 and phenanthroline30 ligands upon coordination to Zn(II). A 
bathochromic shift of the emission band was observed for the Zn(II) complex as expected, 
however the Stokes shift was also seen to decrease. As with the absorption spectrum, 
titration with Zn(II) showed no further changes to the emission spectrum after the addition 
of 5 equivalents of Zn(II) (Figure 5.7C). While the absorption characteristics of compound 
4 are ideal, the very low quantum yield of the Zn(II) complex would make visualizing the 
metal ion in biological systems challenging. 
The quantum yield for compound 6 had previously been reported as f  = 0.93 in aerated 
methanol,31 which we have confirmed here (Table 5.5). The quantum yield for compound 
7 was almost identical to that of compound 6. However, the quantum yields for both 
compounds differ greatly upon coordination to Zn(II), which had not been previously 
reported on. Compound 6 only showed a marginal decrease in quantum yield while 
compound 7 showed a more drastic decrease. However, both Zn(II) complexes were still 
highly fluorescent. The Zn(II) complexes of compounds 6 and 7 showed increased Stokes 
shifts over the free ligands, and bathochromic shifts of the excitation and emission maxima. 
For both compounds 6 and 7, titration of 30 equivalents of Zn(II) was required before no 
further change to the emission spectrum was observed (Figure 5.7D and 5.7E). Since the 
Zn(II) complexes of compounds 6 and 7 both had significant absorption at 405 nm, while 
the free ligands did not, and the quantum yields of the complexes were high, we elected to 
further explore these two ligands for sensing Zn(II) in a biological system by confocal 
microscopy. 
5.2.4 Effects of Other Metal Ions on the Absorption and Emission 
Spectra 
In order to detect Zn(II) in a complex biological system, it is essential that the fluorescence 
response be specific for Zn(II) over other metal ions. The UV/Vis absorption spectra and 
fluorescence emission spectra for compounds 6 and 7 were recorded in the presence of 
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Zn(II), Fe(III), Cu(II), Mg(II) and Ca(II). These metal ions represent the most abundant 
metals in a cellular environment that are likely to cause interference.  For both ligands, the 
addition of Ca(II) and Mg(II) had no effect on the absorption maximum, and minimal effect 
on the extinction coefficient. The addition of Cu(II) resulted in a larger red shift of the 
absorption spectrum than did Zn(II). The addition of Fe(III) had minimal effect on the 
position of the absorption maximum, but greatly increased the extinction coefficients. For 
both ligands Ca(II) and Mg(II) also had no effect on the fluorescence emission spectrum, 
Cu(II) caused complete quenching of fluorescence, and Fe(III) caused a slight 
bathochromic shift with significant quenching (Figure 5.8). 
 
Figure 5.45: UV/Vis absorbance and fluorescence emission spectra of compound 6 (A and 
D, black) and compound 7 (B and D, black) in the presence of Fe(III) (brown), Cu(II) 
(blue), Mg(II) (magenta), Ca(II) (green) and Zn(II) (red). 
5.2.5 Confocal Microscopy of Prostate Cell Lines 
PC-3 and DU 145 prostate cancer cells have been previously shown to have an impaired 
ability to uptake Zn(II).32,33 In contrast BPH-1 cells retain the ability to accumulate high 
levels of intracellular Zn(II). All cell lines were incubated with either compound 6 or 7 at 
a concentration of 20 µM for 60 minutes. After the incubation period, cells were fixed with 
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4% paraformaldehyde and mounted on slides for imaging by confocal microscopy. Weak 
fluorescence was observed in BPH-1 cells after incubation with either compound 6 (Figure 
5.9) or 7 (Figure 5.10) for 60 minutes when excited with a 405 nm laser, and emission 
collected from 475-575 nm. While the free ligands do show some fluorescence emission 
in this range, neither one displays any absorbance at 405 nm. Fluorescence emission then 
should be exclusively from the Zn(II) complexes. Therefore the observed background 
fluorescence is likely due to cellular uptake of Zn(II) present in the culture medium. This 
has been observed with similar fluorescent Zn(II) indicators as well.23 BPH-1 cells 
incubated with either compound 6 or 7 followed by a 60 minute incubation with Zn(II) at 
a concentration of 200 µM showed a large increase in fluorescence intensity. PC-3 and DU 
145 cells displayed no fluorescence upon incubation with compound 6 or 7, and no increase 
in fluorescence intensity was observed upon the addition of Zn(II). These results are 
promising, as bipyridine ligands have the possibility to differentiate benign and malignant 
tissue by Zn(II) mediated fluorescence. Compounds 6 and 7 also have the potential to be 
used for Zn(II) sensing in ex vivo malignant, benign and healthy prostate tissues. 
 
Figure 5.46: (A) BPH-1, (B) DU 145 and (C) PC-3 cells incubated with compound 6 (20 
µM) for 60 minutes. (D) BPH-1, (E) DU 145 and (F) PC-3 cells incubated with compound 
6 (20 µM) for 60 minutes, followed by the addition of ZnSO4 (200 µM) for 60 minutes. 
lEx = 405 nm, lEm = 475-575 nm. 
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Figure 5.47: (A) BPH-1, (B) DU 145 and (C) PC-3 cells incubated with compound 7 (20 
µM) for 60 minutes. (D) BPH-1, (E) DU 145 and (F) PC-3 cells incubated with compound 
7 (20 µM) for 60 minutes, followed by the addition of ZnSO4 (200 µM) for 60 minutes. 
lEx = 405 nm, lEm = 475-575 nm. 
5.3 Conclusions 
In summary, we have shown that amino substituted bipyridine ligands are suitable for the 
detection of Zn(II) by fluorescence. We have investigated the UV/Vis and fluorescence 
properties of five bipyridine ligands in a range of solvents, showing that compounds 2, 4, 
6, and 7 display characteristics of intramolecular charge transfer, while confirming 
previous reports that compound 1 does not. Quantum yields of compounds 1 and 2 were 
rather low but increased 70 and 3-fold respectively upon coordination to Zn(II). Compound 
4 had a similar quantum yield to compound 2 but showed a drastic decrease upon Zn(II) 
coordination. Compounds 6 and 7 had very high quantum yields. While they decreased 
slightly upon Zn(II) coordination, the complexes were still highly fluorescent with 
bathochromically shifted UV/Vis and fluorescence spectra. The fluorescence response for 
compounds 6 and 7 was selective for Zn(II) over other biologically relevant metal ions. We 
have shown that these bipyridine ligands also respond to Zn(II) in a biological system, 
using prostate cells as a model system. BPH-1 cells, which are known to accumulate 
intracellular Zn(II) showed an increase in fluorescence in response to Zn(II) upon 
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incubation with either compound 6 or 7 and excitation at 405 nm. PC3 and DU 145 cells 
did not show an increase in fluorescence intensity, indicating low uptake of Zn(II). We 
have demonstrated the utility of compounds 6 and 7 in detecting Zn(II) in a cellular 
environment. Further investigation of these amino substituted bipyridine ligands may allow 
for quantitative determination of Zn(II) concentrations in ex vivo tissue samples, which 
may be used as a method for differentiating malignant from benign and healthy prostate 
tissue. Furthermore, structural modification of the ligands could allow for lower energy 
fluorescence excitation in order to reduce the possible effects of autofluorescence. 
5.4 Experimental 
General Experimental: All reagents and solvents were purchased from commercial 
sources and used without further purification unless otherwise noted. All reactions were 
performed in oven-dried glassware under nitrogen atmosphere. Analytical thin-layer 
chromatography (TLC) was performed using plastic-backed TLC plates coated with silica 
gel 60 F254. Flash chromatography was performed using a Biotage Isolera Prime on KP-Sil 
cartridges. NMR spectra were recorded on a Bruker AvIII HD 400 spectrometer. All 
chemical shifts are reported in ppm and referenced to the solvent peaks. High resolution EI 
mass spectra were collected on a Thermo Scientific Double Focusing Sector mass 
spectrometer. UV/Vis spectra were recorded on an Agilent Cary 60 UV/Vis 
spectrophotometer. Fluorescence spectra were recorded on a Photon Technologies 
International, Inc. Quanta Master – 7/2005. Quantum yields were determined on aerated 
methanol solutions using quinine sulfate in 0.05 M H2SO4 as a standard (f = 0.52).  3,3’-
Diamino-2,2’-bipyridine (1),24 5,5’-diamino-2,2’-bipyridine (2),25 and 2,2’-bipyridine-
5,5’-dicarboxylic acid (5)27 were synthesized according to previously reported procedures. 
4-(2-chloropyridin-5-yl)aniline (3): A mixture of 5-bromo-2-chloropyridine (500 mg, 2.6 
mmol), 4-aminophenylboronic acid pinacol ester (570 mg, 2.6 mmol), Pd(PPh3)4 (150 mg, 
0.13 mmol), and Na2CO3 (550 mg, 5.2 mmol) in 4:1 dioxane/water (25 mL) was heated at 
reflux for 24 hours. After cooling to room temperature, the solvent was evaporated, and 
the residue taken up in dichloromethane. The organic solution was washed with water and 
brine and filtered over an alumina plug. The solvent was evaporated, and the resulting 
brown semisolid was purified by automated flash chromatography (Snap 50 g KP-Sil, 10-
110 
 
80% EtOAc/Hex) to give the pure product as a beige solid (380 mg, 72%). Rf = 0.38 (40% 
EtOAc/Hexanes); 1H NMR (400 MHz, CDCl3) δ = 8.54 (d, J = 2.3 Hz, 1H), 7.76 (dd, J = 
8.3, 2.6 Hz, 1H), 7.41 – 7.30 (m, 3H), 6.82 – 6.71 (m, 2H), 3.83 (s, 2H); 13C NMR (100 
MHz, CDCl3) δ = 149.1, 147.3, 146.9, 136.3, 135.6, 128.0, 126.4, 124.0, 115.5; HRMS 
(EI): m/z calculated for C11H9ClN2+ [M]+ 204.0454; found 204.0451. 
5,5'-bis-(4-aminophenyl)-2,2'-bipyridine (4): A mixture of 3 (100 mg, 0.49 mmol), 
NiCl2×6H2O (6 mg, 24 µmol), LiCl (21 mg, 0.49 mmol) and Zn dust (38 mg, 0.59 mmol) 
in anhydrous DMF (2 mL) was heated to 50 °C. The reaction was initiated by the addition 
of a small crystal of I2 and one drop of AcOH, resulting in a colour change from blue to 
black. After 2 hours, all starting material had been consumed as indicated by TLC. After 
cooling to room temperature, ethyl acetate (10 mL) was added, resulting in the precipitation 
of the product as the Zn complex. This was collected by filtration and taken up in 1 M HCl 
(3 mL). The solution was then basified by the addition of conc. NH4OH (1 mL), resulting 
in the precipitation of the crude product as a brown solid. The product was collected by 
filtration, triturated with 1,4-dioxane (5 mL), and once again collected by filtration to give 
the pure product as an orange-yellow solid (21 mg, 25%). 1H NMR (400 MHz, DMSO-d6) 
δ = 8.89 (d, J = 1.6 Hz, 2H), 8.37 (d, J = 7.6 Hz, 2H), 8.07 (dd, J = 8.3, 2.4 Hz, 2H), 7.55 
– 7.47 (m, 4H), 6.73 – 6.63 (m, 4H), 5.40 (s, 4H); 13C NMR (100 MHz, DMSO-d6) δ = 
152.9, 149.7, 146.5, 136.2, 133.6, 127.8, 123.9, 120.5, 114.8; HRMS (EI): m/z calculated 
for C22H18N4+ [M]+ 338.1531; found 338.1530.  
5,5'-bis(1H-benzimidazol-2-yl)-2,2'-bipyridine (6): To a 250 mL round bottomed flask 
containing 5 (500 mg, 2.05 mmol) and o-phenylenediamine (443mg, 4.09 mmol) was 
added polyphosphoric acid (~10 mL) and the syrupy suspension was heated to 180 °C in 
an oil bath for 24 hours. Upon cooling to 100 °C, deionized water (200 mL) was slowly 
added to the dark orange solution, resulting in precipitation of a bright yellow solid. The 
flask was removed from the oil bath and stirring continued until all of the viscous 
polyphosphoric acid was mixed with the water. Upon cooling to room temperature, the 
yellow phosphate salt was collected by filtration and dried under vacuum. The solid was 
suspended in deionized water (40 mL), and the pH adjusted to 11 with 6 M potassium 
hydroxide. The suspension was stirred at room temperature for 1 hour. The yellow solid 
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was collected by filtration, and dried in vacuo (594 mg, 75%). 1H NMR (400 MHz, 1:1 
CDCl3:TFA-d) δ = 9.92 – 9.79 (m, 2H), 9.32 – 9.19 (m, 2H), 9.00 – 8.85 (m, 2H), 7.98 – 
7.86 (m, 5H), 7.86 – 7.74 (m, 5H); 13C NMR (100 MHz, 1:1 CDCl3:TFA-d) δ = 148.4, 
146.3, 143.3, 143.0, 131.7, 129.8, 125.5, 123.9, 114.8; HRMS (EI): m/z calculated for 
C24H16N6+ [M]+ 388.1436; found 388.1435. 
5,5'-bis(1-methyl-1H-benzimidazol-2-yl)-2,2'-bipyridine (7): To a solution of 6 (100 
mg, 0.26 mmol) in DMF (5 mL) was added Cs2CO3 (78 mg, 0.57 mmol) and methyl iodide 
(81 mg, 0.57 mmol) and the resulting bright yellow solution was stirred at room 
temperature for 16 hours. The resulting pale-yellow suspension was then diluted with 
deionized water (30 mL), and the beige precipitate was collected by filtration and dried in 
vacuo (43 mg, 40%). 1H NMR (400 MHz, CDCl3) δ = 9.15 (dd, J = 2.2, 0.7 Hz, 2H), 8.69 
(dd, J = 8.2, 0.7 Hz, 2H), 8.33 (dd, J = 8.2, 2.2 Hz, 2H), 7.91 – 7.85 (m, 2H), 7.48 – 7.44 
(m, 2H), 7.42 – 7.33 (m, 4H), 3.98 (s, 6H); 13C NMR (10 MHz, CDCl3) δ = 156.2, 150.8, 
149.6, 143.3, 138.0, 136.9, 126.9, 123.6, 123.1, 121.4, 120.3, 110.0, 32.0; HRMS (EI): m/z 
calculated for C26H19N6+ [M-H]+ 415.1666; found 415.1665. 
Cell Culture: PC-3 and DU 145 cells were purchased from ATCC. BPH-1 cells were a 
generous gift from Dr. John Lewis (University of Alberta, Edmonton, Alberta). PC-3 cells 
were maintained in F-12K medium (Wisent) supplemented with 10% FBS and 1X 
penicillin-streptomycin. DU 145 cells were maintained in EMEM (Sigma) supplemented 
with 10% FBS, 1X MEM non-essential amino acids (Sigma), 2 mM L-glutamine, 1 mM 
sodium pyruvate and 1X penicillin-streptomycin.  BPH-1 cells were maintained in RPMI 
1640 medium (Wisent) containing 10% FBS and 1X penicillin-streptomycin. All cell lines 
were cultured in a 37 °C incubator with a 5% CO2 atmosphere. Cells were passaged 2-3 
times per week.  
Fluorescence Imaging by Confocal Fluorescence Microscopy: In 12-well plates 
containing glass coverslips, PC-3, DU 145 and BPH-1 cells were seeded at a density of 
100,000 cells per well and allowed to adhere and grow for 24-48 hours. The culture 
medium was removed, and the wells washed with PBS (2 x 1 mL). A stock solution of 
bipyridyl ligand (200 µL, 1 mM in DMSO) was diluted in culture media (10 mL) giving a 
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20 µM solution, which was filtered through a 0.2 µm syringe filter to remove any 
precipitates. This solution (1 mL) was added to each well, and the cells incubated for 60 
minutes at 37 °C. The culture media was removed and each well washed with PBS (2 x 1 
mL). Two wells were then incubated with a 200 µM solution of ZnSO4×7H2O in culture 
media (1 mL) for 60 minutes at 37 °C. The culture media was removed, and the cells 
washed twice with PBS. The cells were then fixed by the addition of 1 mL of a 4% 
paraformaldehyde solution in PBS (1 mL) for 15 minutes. After washing with PBS (2 x 1 
mL), the cells were mounted on glass slides using ProLong® Diamond Antifade Mountant 
(Invitrogen) for imaging. Confocal fluorescence microscopy was performed on an 
Olympus FluoView FV1000 Confocal Microscope using a 40x objective with a 405 nm 
laser for excitation and the emission range set to 475-575 nm. 
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Chapter 6 
6 Conclusions 
The field of molecular imaging has provided clinicians and scientists a deeper 
understanding of disease, and the underlying cellular and molecular processes. A large tool 
palette of molecular imaging agents is available, ranging from PET, SPECT and MRI 
imaging probes for in vivo diagnostic imaging, and fluorescent OI imaging probes for 
preclinical research applications in cells and tissues. However, there are still unmet needs 
in both clinical and research settings for molecular imaging probes that must be 
addressed.1–3 Therefore, novel methodologies and approaches to the design of molecular 
imaging probes must be taken in order to develop agents that improve upon those that exist 
or allow for imaging of new biological targets. 
Molecular imaging agents that target GPCRs have become an approach to personalized 
medicine in a clinical setting. Determining expression of these receptors in disease allows 
for targeted therapeutic approaches, as well as more accurate and sensitive imaging of 
disease distribution in the body.4 The GPCR CXCR4 has garnered much attention as a 
target for molecular imaging probes in cancer. In chapter 2, the development of a novel 
dual modality molecular imaging probe targeting CXCR4 was explored. Dual modality 
imaging agents allow for a single entity to be used in different imaging applications, or for 
two modalities to be used simultaneously to overcome the disadvantages of each 
modality.5,6 It had previously been reported that 4-amino-1,8-naphthalimides containing a 
di-(2-picolyl)amine chelator coordinated to rhenium are suitable as fluorescent cellular 
imaging agents.7 Replacement of rhenium with technetium-99m opens the doors for the 
development of SPECT imaging agents. Though many fluorescent rhenium complexes 
have been reported that may also be coordinated to technetium-99m for SPECT imaging, 
these agents often suffer from low quantum yields, and the energy required for excitation 
is in the UV range.8 This is not ideal for imaging of live cells and tissues, so new agents 
with visible light excitation would help to improve the utility of fluorescent rhenium 
complexes for imaging applications. 
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A 4-amino-1,8-naphthalimide containing a carboxylic acid functionality was synthesized 
and conjugated to the D-Lys side chain of the CXCR4 antagonist peptide T140. The peptide 
was coordinated to rhenium for in vitro characterization. The rhenium coordinated peptide 
retained high fluorescence quantum yields. Through competition binding assays, it was 
determined that the rhenium coordinated peptide retained high affinity for CXCR4. By 
confocal fluorescence microscopy, it was shown that the peptide was taken up selectively 
by cells expressing CXCR4. This provides a possible route to differentiate malignant 
prostate cells from healthy and benign, as only malignant cells express CXCR4. 
Radiolabelling with technetium-99m was achieved in high radiochemical yield, purity and 
molar activity. To my knowledge, this is the first report of a 99mTc(CO)3-labelled CXCR4 
imaging agent, and the first 99mTc-labelled T140 derivative. Other technetium-99m labelled 
imaging agents targeting CXCR4 use the 99mTc-HYNIC9 or 99mTcO2+ scaffolds,10,11 which 
tend to exhibit lower in vivo stability than the 99mTc(CO)3 system. These types of 
complexes also do not produce rhenium complexes that exhibit luminescence properties. 
Peptides such as T140 also provide the opportunity for optimizing structures to improve 
biodistribution and pharmacokinetics. Cellular uptake of the radiotracer in CXCR4 
expressing cells was two-fold of that in cells that do not express the receptor. 
Disappointingly, in NOD/SCID mice bearing CXCR4 expressing tumors, uptake of the 
technetium-99m labelled tracer was rather low. A possible reason for the low uptake is the 
lipophilic nature of the naphthalimide entity, as this has been shown to cause non-specific 
binding in other organs. Even though the metal complex bears a positive charge, the non-
polar nature of the aromatic pyridyl ligands appears to overpower the effects of the charge. 
There are several possibilities on how to improve the pharmacokinetic profile of the 
radiotracer. Previously reported CXCR4 targeting PET imaging probes that had low tumor 
uptake saw a reduction in non-specific binding upon lowering the molar activity of the 
radiotracer.12,13 Another feasible approach is to reduce the lipophilicity of the 
naphthalimide by altering the metal chelation system. This may help to reduce non-specific 
binding in vivo. This newly developed dual modality imaging agent shows promise as a 
tool for evaluating CXCR4 expression in cells and tissues by fluorescence imaging, 
however improvements are required before it may be used as a SPECT imaging agent.  
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As seen in chapter 2, peptides containing technetium-99m labelled 4-amino-1,8-
naphthalimides may suffer from poor pharmacokinetics in vivo due to their lipophilic 
nature. Therefore, the development of less lipophilic naphthalimide-metal complexes is 
required in order to address this issue. In order to be useful as dual modality imaging agents, 
the fluorescence properties must be suitable for fluorescence imaging. In chapter 3, the 
synthesis and evaluation of Re/99mTc coordinated naphthalimides containing three different 
chelation systems was discussed. The three ligands were coordinated to rhenium to 
evaluate the fluorescence and cellular uptake properties. The fluorescence properties of the 
rhenium complexes were all suitable for use in confocal fluorescence microscopy. Upon 
incubation with OVCAR-8 cells, it was demonstrated that the cellular uptake of all three 
complexes was drastically different. The ligands containing carboxylate chelating arms 
showed much lower uptake into the cells, indicating a more polar metal complex. The three 
ligands were also radiolabelled with technetium-99m giving high radiochemical yields and 
purities. This demonstrates the three ligands’ utility as components of SPECT imaging 
agents. This may allow for the tuning of the pharmacokinetic profiles of bioconjugates for 
SPECT imaging, while still retaining utility as fluorescence imaging agents.  
Cellular localization and uptake of luminescent metal complexes not only has implications 
for imaging, but for therapeutics as well. Fluorescence imaging of the cellular localization 
of metal complexes may allow for the determination of the mechanism of action of a 
potential therapeutic agent. Luminescent ruthenium-polypyridyl complexes bearing 
positive charges showed higher uptake in cancer cells than those bearing negative charges, 
and both complex types had very different cellular localization.14 While the positively 
charged complex displayed significant cytotoxicity in both dark and light conditions due 
to the mitochondrial localization, the negatively charged complex only displayed toxicity 
upon illumination. This provides the opportunity to develop the complex as an agent for 
photodynamic therapy. Visualization of the change in cellular localization upon modifying 
the complex charge allowed for the determination of the mechanism of action of this 
potential therapeutic agent. Therefore, luminescent metal complexes are a powerful tool 
for studying disease. 
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While pendant labelling approaches to molecular imaging probes such as that demonstrated 
in chapter 2 may not affect a peptides ability to bind to a receptor, in many cases pendant 
labels can be detrimental to binding affinity. Integrated labelling approaches may be 
beneficial for maintaining high affinity for receptors. However, as demonstrated in chapter 
4, the design and implementation of integrated molecular imaging probes presents many 
challenges. An Fmoc-protected amino acid containing a 3,3’-diamino-2,2’-bipyridine 
residue was successfully synthesized and was incorporated into a peptide through SPPS. 
CD spectroscopy showed that the peptide exists in a random coil conformation in an 
aqueous environment. Addition of the secondary structure stabilizing solvent TFE resulted 
in a secondary structure that more closely resembles a b-sheet. However, coordination of 
the bipyridine peptide to rhenium and technetium-99m resulted in unstable metal 
complexes that could not be successfully purified or isolated. As previous reports have 
shown that bipyridine containing peptides can form b-sheet structures upon metal 
coordination,15 and bipyridine complexes of rhenium and technetium-99m are well 
known,16,17 it is feasible that they may be used in the development of SPECT imaging 
agents containing technetium-99m. The instability of the reported metal complexes results 
from steric clash of the 3,3’-substituents on the bipyridine rings, therefore, the use of either 
6,6’- or 4,4’-disubstituted bipyridines may be more suitable for this use case. Other 
methods for incorporating Re/99mTc into turn mimics have been reported,18 so there is 
certainly promise for the field. 
Chapter 5 discussed the development of amino-substituted 2,2’-bipyridine ligands as 
fluorescent indicators for Zn(II) in a cellular environment. 3,3’-Diamino- and 5,5’-
diamino-2,2’-bipyridine ligands showed a strong fluorescent response to Zn(II), displaying 
a large increase in quantum yield in the presence of the metal ion. However, the excitation 
wavelengths required for fluorescence were in the UV region of the electromagnetic 
spectrum, which is not ideal for use in fluorescence imaging of live cells. The addition of 
aminophenyl substituents resulted in a ligand with ideal excitation wavelengths for live 
cell imaging upon coordination to Zn(II), however, the complex was only weakly 
fluorescent. Two benzimidazole substituted 2,2’-bipyridine ligands however, gave good 
quantum yields upon coordination with Zn(II) and were excitable with visible light for 
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cellular imaging. The fluorescence response of the ligands was selective for Zn(II) over 
other metal ions. The two bipyridine ligands were employed for cellular imaging of Zn(II) 
concentrations in prostate cell lines. A fluorescence response was observed in BPH-1 cells 
but not PC-3 and DU 145 PCa cell lines, due to the impaired Zn(II) uptake of the PCa cells. 
This allows for the differentiation of benign and malignant prostate tissues, which may 
have applications in imaging of ex vivo tissue samples. 
Though the field of fluorescent Zn(II) indicators is certainly a crowded one, the need for 
new indicators still exists.3 A fluorescent 3-hydroxychromone Zn(II) sensor was previously 
shown to be able to differentiate between regular prostate epithelial cells and prostate 
cancer cells using two-photon excitation fluorescence microscopy.19 We have 
demonstrated that the same can be done with benign prostate cells using confocal 
fluorescence microscopy with visible light excitation. Previously reported 2,2’-bipyridine 
Zn(II) sensors have been used to detect intracellular Zn(II), but unfortunately could only 
be excited with UV light,20 or suffer from poor photostability.21 The 2,2’-bipyridine Zn(II) 
sensors reported in this thesis are excitable with visible light upon coordination to Zn(II), 
and are therefore more applicable for imaging of live cells. Fluorophores that are able to 
be used ratiometrically, and that are useful over a wide range of concentrations, as well as 
having defined cellular localization may improve the use of these sensors in the study and 
diagnosis of disease. Two-photon excitation microscopy has recently been employed for 
ratiometric sensing of intracellular Zn(II) with the sensor Chromis-1.22 Attachment of 
organelle targeting tags to Zn(II) sensitive probes has also been demonstrated to allow for 
the detection of Zn(II) in specific organelles such as mitochondria.23 
In summary, this thesis has highlighted the development of several novel approaches to 
molecular imaging agents. Novel methodologies and approaches to incorporating imaging 
moieties into molecular imaging agents can lead to the development of new classes of 
probes that target cellular and molecular entities that were not previously accessible. The 
development of new ways to diagnosis and treat disease may be uncovered through 
molecular imaging. Fluorescent naphthalimides containing a variety of metal chelators 
may allow for the development of new fluorescent imaging agents that could also be used 
for nuclear imaging applications. Alteration of the metal complex allows for the tuning of 
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the pharmacokinetic properties of the radiolabelled agent, while still retaining suitable 
fluorescence properties. The design of integrated radiopharmaceuticals presents many 
challenges, and while incorporation of metal chelators into the backbone of peptides is 
certainly possible, the coordination chemistry of the ligand must be carefully tuned in order 
to provide stable metal complexes that may be used for in vivo imaging applications. 
Though a metal chelator may not be suitable for one application, often other applications 
for the molecule may be explored. For example, the 3,3’-diamino-2,2’-bipyridine ligands 
developed in chapter 4 were not suitable for coordination to Re/99mTc. However, the 
discovery of their fluorescence properties upon coordination to Zn(II) paved the path for 
the development of the bipyridine ligands reported in chapter 5. These bipyridine ligands 
showed strong fluorescent responses to the presence of Zn(II), and are promising agents 
for diagnosing malignancies of the prostate. 
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Appendix A: Additional Data for Chapter 2 
 
Figure A48: 1H NMR spectrum (400 MHz; CDCl3) of compound 5 (DPA-Naph-OH). 
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Figure A49: 13C NMR spectrum (100 MHz; CDCl3) of compound 5 (DPA-Naph-OH). 
 
Figure A50: HPLC chromatogram (10-70% CH3CN/H2O + 0.1% TFA) of peptide 6 
(T140). 
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Figure A51: HPLC chromatogram (20-80% CH3CN/H2O + 0.1% TFA) of peptide 7 
(DPA-Naph-T140). 
 
Figure A52: HPLC chromatogram (20-80% CH3CN/H2O + 0.1% TFA) of peptide Re-7 
(Re(CO)3-DPA-Naph-T140). 
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Table A8: Ex vivo biodistribution data for [99mTc]Tc-7 in NOD/SCID mice two hours 
post-injection (n = 3). 
Tissue Uptake (% ID/g ± SD) 
blood 1.91 ± 0.16 
heart 0.93 ± 0.04 
lung 2.80 ± 0.63 
liver 22.67 ± 5.02 
spleen 2.05 ± 1.37 
pancreas 1.15 ± 0.54 
stomach 4.67 ± 0.99 
intestine 2.36 ± 1.40 
kidney 25.69 ± 15.19 
tumor 0.51 ± 0.09 
muscle 0.26 ± 0.07 
brain 0.10 ± 0.02 
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Appendix B: Additional Data for Chapter 3 
 
Figure B53: 1H NMR spectrum (400 MHz; CD3OD) of compound 3. 
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Figure B54: 13C NMR spectrum (100 MHz; CD3OD) of compound 3. 
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Figure B55: 1H NMR spectrum (400 MHz; CDCl3) of L1. 
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Figure B56: 13C NMR spectrum (100 MHz; CDCl3) of L1. 
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Figure B57: 1H NMR spectrum (400 MHz; acetone-d6) of Re-L1. 
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Figure B58: 13C NMR spectrum (100 MHz; acetone-d6) of Re-L1. 
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Figure B59: 1H NMR spectrum (400 MHz; CD3OD) of L2. 
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Figure B60: 13C NMR spectrum (100 MHz; CD3OD) of L2. 
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Figure B61: 1H NMR spectrum (400 MHz; CD3CN) of Re-L2. 
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Figure B62: 1H NMR spectrum (400 MHz; CD3OD) of L3. 
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Figure B63: 13C NMR spectrum (100 MHz; CD3OD) of L3. 
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Figure B64:  1H NMR spectrum (400 MHz; CD3OD) of Re-L3. 
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Figure B65:  13C NMR spectrum (100 MHz; CD3OD) of Re-L3. 
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Figure B66: Confocal microscope images of OVCAR-8 cells incubated with Re-L1 (A, 
D) Re-L2 (B, E) and Re-L3 (C, F) at a concentration of 20 µM (lEx = 458 nm, 40x 
objective). 
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Figure B67: Confocal microscope images (lEx = 458 nm, 100x objective) of OVCAR-8 
cells incubated with Re-L1 (left), Re-L2 (middle) and Re-L3 (right). Top panel are 
fluorescence images, bottom panel are fluorescence images overlaid with DIC images. 
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Appendix C: Spectra of Compounds from Chapter 4 
 
Figure C68: 1H NMR spectrum (CDCl3; 400 MHz) of compound 1. 
 
Figure C69: 13C NMR spectrum (CDCl3; 100 MHz) of compound 1. 
142 
 
 
Figure C70: 1H NMR spectrum (CDCl3; 400 MHz) of compound 2. 
 
Figure C71: 13C NMR spectrum (CDCl3; 100 MHz) of compound 2. 
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Figure C72: 1H NMR spectrum (CDCl3; 400 MHz) of compound 3. 
 
Figure C73: 13C NMR spectrum (CDCl3; 100 MHz) of compound 3. 
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Figure C74: 1H NMR spectrum (CDCl3; 400 MHz) of compound 4. 
 
Figure C75: 13C NMR spectrum (CDCl3; 100 MHz) of compound 4. 
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Figure C76: 1H NMR spectrum (DMSO-d6; 400 MHz) of compound 5. 
 
Figure C77: 13C NMR spectrum (DMSO-d6; 100 MHz) of compound 5. 
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Figure C78: 1H NMR spectrum (DMSO-d6; 400 MHz) of compound 6. 
 
Figure C79: 13C NMR spectrum (DMSO-d6; 100 MHz) of compound 6. 
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Appendix D: Additional Data for Chapter 5 
 
Figure D80: 1H NMR Spectrum (CDCl3; 400 MHz) of Compound 1. 
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Figure D81: 13C NMR Spectrum (CDCl3; 100 MHz) of Compound 1. 
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Figure D82: 1H NMR Spectrum (DMSO-d6; 400 MHz) of Compound 2. 
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Figure D83: 13C NMR Spectrum (DMSO-d6; 100 MHz) of Compound 2. 
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Figure D84: 1H NMR Spectrum (DMSO-d6; 400 MHz) of Compound 4. 
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Figure D85: 13C NMR Spectrum (DMSO-d6; 100 MHz) of Compound 4. 
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Figure D86: 1H NMR Spectrum (1:1 CDCl3:TFA-d; 400 MHz) of Compound 6. 
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Figure D87: 13C NMR Spectrum (1:1 CDCl3:TFA-d; 100 MHz) of Compound 6. 
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Figure D88: 1H NMR Spectrum of (CDCl3; 400 MHz) Compound 7. 
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Figure D89: 13C NMR Spectrum (CDCl3; 100 MHz) of Compound 7. 
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Figure D90: UV/Vis absorption spectra of: (A) compound 2; (B) compound 4; (C) 
compound 6; and (D) compound 7 in various solvents. 
 
Figure D91: Fluorescence emission spectra of compound 2 (20 µM) in non-polar (left) and 
polar solvents (right) with 40 µM DIPEA. 
 
 
158 
 
 
Figure D92: Fluorescence emission spectra of compound 6 (20 µM) (top) and compound 
7 (20 µM) in non-polar (bottom left) and polar (bottom right) solvents. 
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Table C9: Photophysical Properties of Compound 6 in Various Solvents. 
 CyH[a] DX CHCl3 DCM[a] EtOH MeOH CH3CN[a] DMF DMSO 
e 2.02 2.22 4.81 8.93 25.3 33 36.6 38.3 47.2 
lAbs 
(nm) 
- 361 358 - 359 356 - 364 366 
lEx 
(nm) 
- 362 355 - 359 358 - 364 365 
lEm 
(nm) 
- 415 407 - 425 433 - 425 431 
SS 
(cm-1) 
- 3528 3599 - 4326 4838 - 3943 4195 
[a]Insoluble 
 
Figure D93: Fluorescence excitation and emission spectra of compound 2 in methanol 
(black), upon the addition of base (blue) and upon the addition of acid (red). 
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Figure D94: Fluorescence excitation and emission spectra of the Zn(II) complexes of: 
(A) compound 1; (B) compound 2; (C) compound 4; (D) compound 6; and (E) compound 
7 in methanol. 
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